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Staphylococcus aureus is a major human pathogen found worldwide, causing a wide variety 
of clinical infections. This ranges from skin and soft tissue infections to life-threatening 
invasive disease, such as S. aureus bacteraemia (SAB). Despite being a common cause of both 
community-acquired and hospital-acquired infections, limited evidence exists on the 
management and outcomes of Staphylococcus aureus bacteraemia (SAB) in resource-limited 
settings. The aim of this study was to describe a cohort of South African patients with SAB, 
and explore the factors associated with complicated infection and death. A prospective 
observational study was performed of patients over the age of 13 years admitted to a South 
African referral hospital with SAB. Data were analysed using Kaplan Meier survival models 
and linear regression models.  
One hundred consecutive SAB infection episodes in 98 patients were included. SAB was 
healthcare-associated in 68.4%, with 57.6% of these linked to drip site infection; 24.0% of all 
cases were caused by methicillin-resistant S. aureus (MRSA). Ninety-day mortality was 47.0%, 
with 83.3% of deaths attributable to SAB. Predictors of 90-day mortality were MRSA (odds 
ratio (OR) 1.28; 95% confidence interval (CI) 1.0 to 15.1) and the presence of co-morbidities 
(OR 4.1; 95% CI 1.0 to 21.6). The risk of complicated infection was higher with suboptimal 
antibiotic therapy (OR 8.5; 95% CI 1.8 to 52.4), female sex (OR 3.8; 95% CI 1.1 to 16.3) and 
community-acquired infection (OR 7.4; 95% CI 2.0 to 33.1). Definitive antibiotic therapy was 
suboptimal in 22.6% of all cases. Overall, SAB-related mortality was high. A large proportion 
of SAB episodes may be preventable, and there is a need for improved antibiotic management 
in this setting. 
Part A. The study protocol, as submitted for departmental and ethical approval, is presented 
here. It includes the background, rationale and methodology of the research done for this 
mini-dissertation. 
Part B. A structured literature review is presented of articles pertaining to SAB epidemiology 






Part C. A journal-ready manuscript according to the requirements of the International Journal 
of Infectious Diseases. 
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 Part A. Research Protocol 
1. Introduction and statement of purpose 
Staphylococcus aureus bacteraemia (SAB) is an important cause of mortality and morbidity 
globally; outcomes are even worse with methicillin-resistant Staphylococcus aureus (MRSA), 
which is becoming a more frequent cause of SAB.  While recommendations for the management 
of Staphylococcus aureus bacteraemia exist and are widely distributed, this disease is 
notoriously poorly managed. Much research has been done into the risk factors and outcomes 
of SAB, however very little quality evidence has been generated in a South African setting, 
which may have different outcomes compared with high income countries because of high rates 
of HIV and other infectious comorbidities.  
The purpose of this observational study is to describe the clinical characteristics, management, 
and outcomes of patients presenting with Staphylococcus aureus bacteraemia in a referral 
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2.  Background to the study 
2.1 Introduction 
Staphylococcus aureus is a major human pathogen found worldwide, causing a wide range of 
clinical infections from skin and soft tissue infections to life-threatening invasive disease. S. 
aureus bacteraemia (SAB) is associated with a high mortality and is a common infection in both 
community and health care settings. Multiple studies have documented the prevalence and 
outcome of SAB in high income countries, however there remains a paucity of knowledge 
regarding SAB in low and middle-income countries (LMIC). A global concern is also the lack of 
high-quality evidence to guide the management of SAB.  
2.2 Clinical Burden 
In higher income regions, the population incidence of SAB ranges from 10 to 30 per 100 000 
person-years, with S. aureus being the second most common cause of nosocomial bloodstream 
infections in the United States (US) (Laupland et al. 2013). Large geographical discrepancies in 
SAB incidence likely reflect differences in health care systems, infection control practices, and 
the completeness of surveillance data (Van Hal et al. 2012). Healthcare-associated SAB (HCA-
SAB) is associated with higher mortality, longer length of stay, and greater total hospital costs 
compared to bacteraemia of any other cause in the US (Shorr et al. 2006). 
Less is known about the incidence and impact of SAB in relatively lower income regions 
such as Sub-Saharan African. It is likely comparable to high income nations, and may be higher 
due to the influence of HIV (Larsen et al. 2012). A systematic review of 22 studies reporting 
causes of bloodstream infections on the continent found the overall prevalence of SAB amongst 
adult patients admitted with bloodstream infections to be 5.4% (111 of 2078 isolates) (Reddy 
et al. 2010). At Groote Schuur Hospital (GSH), an informal review of blood cultures performed 
in 2012 showed that S. aureus was the second most common pathogen recovered after 
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2.3 Risk factors 
Various patient factors affect the risk of developing SAB, with the most important of these 
being the presence of intravascular foreign material, such as peripheral or central intravenous 
catheters (Jensen et al. 1999), as well as the presence of other prosthetic material, such as 
joints or heart valves. Patients receiving haemodialysis are thus at a greatly increased risk of 
SAB (Kallen et al. 2010; Fitzgerald et al. 2017). 
Extremes in age have been shown to be associated with increased SAB incidence (Laupland & 
Church 2014; Allard et al. 2008; Asgeirsson et al. 2011; Huggan et al. 2010). SAB is also more 
commonly found amongst males, with a male to female ratio of 3:2 (Allard et al. 2008; Klevens 
et al. 2007; Asgeirsson et al. 2011; Huggan et al. 2010), however a cohort study in Denmark 
showed that female patients with community-acquired SAB (CA-SAB) experienced increased 
30-day mortality compared with male patients (Smit et al. 2017), suggesting gender should be 
considered in the triage and risk stratification of community-acquired (CA)-SAB patients. 
Ethnicity is also associated with different incidences of SAB, with higher incidences on 
non-white populations (Klevens et al. 2007; Johnson et al. 2005; Cookson et al. 2012). Analysis 
of socioeconomic disparities between ethnic groups has not been shown fully to account for 
these differences in incidences (Tong SY, van Hal SJ, Einsiedel L, Currie BJ 2012).  The 
contribution of host genetic susceptibility to these ethnic differences has not yet been 
investigated. 
The HIV-infected population has a significantly increased incidence of SAB (Larsen et al. 
2012; Wilson et al. 2008), irrespective of the use of intravenous drugs (Wilson et al. 2008). A 
lower CD4 count has been independently associated with SAB. Intravenous drug use is a risk 
factor for higher rates of SAB incidence in all groups, independent of HIV status (Spijkerman et 
al. 1996; Palepu et al. 2001; Tuazon & Sheagren 1974). 
2.4 Methicillin-resistant S. aureus (MRSA) 
The development of methicillin resistance in S. aureus is associated with increases in mortality, 
morbidity, length of hospitalisation and cost of health care (Cosgrove 2006). The contribution 
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(Johnson et al. 2012; Cookson et al. 2012; Kallen et al. 2010; Jarvie et al. 2008; Jarlier et al. 
2010), likely linked to improvements in infection control procedures. In South Africa, the 
prevalence of S. aureus infections that showed MRSA was 24% between 2007 and 2011 in state 
sector hospitals (Naidoo et al. 2013), and over 30% in private institutions (Brink et al. 2007). 
2.5 Clinical manifestations 
The presence of various primary clinical foci for SAB may be identified, with common sources 
being peripheral vascular catheter-related infections, skin and soft tissue infections, 
pleuropulmonary infections, osteoarticular infections and infective endocarditis (IE) (Tong SY, 
van Hal SJ, Einsiedel L, Currie BJ 2012; Laupland et al. 2008; Nickerson et al. 2009; Bishara et al. 
2012; Bassetti et al. 2011; Turnidge et al. 2009; Kaasch et al. 2014). However, a focus of infection 
is not found in approximately 25% of cases, and is associated with worse outcomes than lower 
risk sites, such as intravenous and urinary tract catheters (Van Hal et al. 2012). 
SAB can be classified as “complicated” or “uncomplicated”. This designation has 
important implications for investigations, duration of antibiotic treatment, and overall 
prognosis. The following criteria are used to define uncomplicated SAB: (i) exclusion of IE by 
echocardiography, (ii) no implanted prostheses, (iii) negative results of follow-up blood cultures 
drawn 2 to 4 days after the initial set, (iv) defervescence within 72 h after the initiation of 
effective antibiotic therapy, and (v) no evidence of metastatic infection (Fowler et al. 2003). 
Any other patient should be considered to have complicated SAB. Complicated SAB has been 
shown to occur in over 40% of cases (Fowler et al. 2003). Establishing the status of individual 
patients with regard to each of these criteria allows appropriate decisions to be made about 
subsequent treatment duration, which is longer in complicated infections. 
The 12-week all-cause mortality ranges between 18 and 30% (Forsblom et al. 2011; 
Kaasch et al. 2014), varying according to organism-related factors, such as the presence of 
cloxacillin resistance (Fowler et al. 2003; Wyllie et al. 2006). A lack of improvement in patient 
outcomes could reflect both a relative decrease in antibiotic efficacy and larger numbers of 
older, “sicker” patients that now acquire SAB (Tong et al. 2015). Infection-related mortality is 
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Predictors of mortality from SAB include increasing age, the presence of co-morbid 
conditions, the absence of an identifiable source, extent, and persistence of infection, initial 
inadequate antibiotic treatment, and failure to achieve source control (Turnidge et al. 2009; 
Bassetti et al. 2011). Several studies have also shown infection with MRSA to be an independent 
risk factor for mortality in SAB (Cosgrove 2006; Naidoo et al. 2013). Delayed initiation of optimal 
antibiotic therapy by 2 days has been shown to more than double the risk of mortality 
(Marchaim et al. 2010; Lodise et al. 2003). 
 2.6 Management 
Both US and UK guidelines for the management of MRSA-bacteraemia (MRSA-B) are available, 
and recommend a minimum of 2 weeks intravenous therapy for patients with uncomplicated 
SAB, and longer (4–6 weeks) intravenous antibiotic therapy for those with complicated 
infections (Liu et al. 2011; Gemmell et al. 2006). Evidence to support various recommendations 
has been comprehensively reviewed, and is however largely considered to be of a poor quality. 
Only a single small randomised control trial (RCT) has been performed to examine the optimal 
duration of antibiotic therapy for any form of SAB (Rahal 1986). 
The South African Antibiotic Stewardship Programme (SAASP) has developed an 
evidence-based antibiotic prescribing guideline, including an algorithm for the treatment of SAB 
(Wasserman et al. 2014). A minimum of 4 weeks’ antibiotic therapy is advised for patients with 
prosthetic heart valves or endocarditis, persistent bacteraemia or fever after 72 hours of 
antibiotic therapy, or a non-removable or deep-seated site of infection, such as bone.  
The involvement of infectious diseases specialists is an important aspect of 
management. Recommended management strategies are carried out significantly more 
frequently among patients seen by an infectious diseases specialist, contributing to the survival 
benefit (Paulsen et al. 2015; Liu 2013; Vogel et al. 2017).   
Administration of appropriate antibiotic therapy has an important influence on the 
outcomes of both methicillin-sensitive S. aureus (MSSA) and MRSA (Van Hal et al. 2012).  A 
meta-analysis of 6 studies demonstrated an almost 2-fold survival benefit (OR, 1.84; 95% CI 1.25 
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The treatment of choice for SAB remains cloxacillin or cefazolin (or penicillin if susceptible) for 
MSSA and vancomycin for MRSA. 
One intervention in SAB management that is supported by high quality evidence is early 
source control, with surgical drainage of collections and removal of intravascular catheters 
(Thwaites et al. 2017).  
Imaging of the cardiac valves is performed in cases of SAB to determine if there is 
underlying IE present, however it is unresolved whether transoesophageal echocardiography 
(TOE) is required in all such patients. The SAASP guidelines for SAB recommend 
echocardiography for the following patients: implanted prosthetic heart valves; clinical 
evidence of endocarditis; and community-acquired infection, which is associated with an 
increased risk of complicated SAB. The absence of clinical and microbiological features of 
complicated SAB have a good negative predictive value (93 to 100%) for endocarditis, and may 
be used in these settings to identify low risk patients who do not require echocardiography 
(Holland et al. 2014).  
2.7 Studies from South Africa 
Only four clinical studies of SAB have been conducted in South Africa, two of which were 
retrospective in design  (Smidt et al. 2015; Naidoo et al. 2013; Perovic et al. 2006; Willcox et al. 
1998). A prospective study of 113 consecutive episodes of CA-SAB was conducted at GSH over 
the years 1986 to 1991 (Willcox et al. 1998). The overall mortality was 35% at 3 months, and 
complications occurred in 90% of patients, including endocarditis in 17%. A recent prospective 
study was conducted across three Johannesburg public sector hospitals to describe the 
epidemiology of MRSA-B and factors associated with poor outcomes (Smidt et al. 2015). The 
overall proportion of MRSA-B was 36%. The number of patients with complicated SAB was not 
reported, nor were the overall outcomes and choice and timing of antibiotic therapy.  
Because of the paucity of good quality data, the contemporary management and 
outcomes of SAB in South Africa is not well understood. The proposed study aims to address 
this knowledge gap by analysing prospectively collected clinical data of consecutive patients 
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3.  Aims and objectives 
3.1 Aim 
This study aims to improve the recognition and management of SAB by characterising the 
clinical phenotype in a South African population, as well as exploring the factors associated 
with poor outcomes. 
3.2 Objectives 
1. To describe the demographics and clinical characteristics of South African patients with SAB, 
as well as the microbiological profile of S. aureus isolates. 
2. To determine the outcomes of patients with SAB at 90 days after the initial blood culture, 
stratified by CA and HCA, and MRSA and MSSA.  
3. To describe the management of SAB, including timing and choice of antibiotic therapy. 
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4. Methodology 
4.1 Definition of terms 
Classification of bacteraemia (Friedman et al. 2002):  
▪ Community-acquired: positive blood culture obtained at the time of admission or ≤ 48 
hours after admission. 
▪ HCA – hospital onset (HCA-HO): positive blood culture first obtained ≥ 48 hours after 
admission. 
▪ HCA – community onset (HCA–CO): positive blood culture obtained ≤ 48 hours after 
admission if the patient (a) had intravenous therapy in the previous 30 days; (b) 
attended a hospital or received dialysis in the previous 30 days; or (c) resided in a nursing 
home or long-term care facility. 
Source of infection:  
▪ Localising symptoms or signs of infection likely to have preceded bacteraemia. 
▪ Drip site definite: active drip site inflammation in previous 30 days. 
▪ Drip site probable: HCA SAB in a patient with a current or recent (within 30 days) 
intravenous line and no other clinical focus of infection. 
Complicated SAB:  
▪ The presence of 1 or more of the following: 
o Persistent bacteraemia ≥ 72 hours after therapy with an antibiotic to which the 
isolate has in vitro susceptibility 
o Metastatic infection or deep-seated abscess 
o Endocarditis 
Cause of death:  
▪ Death was considered to be infection-related if there were persistent signs and 
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Antibiotic therapy (Asgeirsson et al. 2011; Chang et al. 2003): 
▪ Definitive: antibiotic started after the results of a positive blood culture with S. aureus 
are called out by the microbiology laboratory. 
o Appropriate: use of cloxacillin (at 2 g 6-hourly for uncomplicated infection or 3 g 
6-hourly if complicated infection) or penicillin if susceptible for MSSA; or 
vancomycin (with a loading dose of 25–30 mg/kg followed by 15–20 mg/kg 12-
hourly) for MRSA.  
o Semi-appropriate: use of cloxacillin < 12 g/day for complicated SAB.  
o Inappropriate: use of cloxacillin or vancomycin at less than half of standard doses 
for SAB (or without a loading dose of vancomycin). 
▪ Empiric: antibiotic started at the time of the index blood culture. 
o Adequate: use of optimal therapy or another antibiotic to which the isolate has 
in vitro susceptibility. 
o Inadequate: use of an antibiotic to which the isolate is not susceptible; use of 
cloxacillin or vancomycin at less than half of standard doses for SAB (or without 
a loading dose of vancomycin).  
▪ Duration of definitive therapy according to SAASP guidelines 
o Appropriate: ≥ 14 days if no endovascular prosthetic material or endocarditis; 
resolution of fever and bacteraemia within 72 hours of adequate therapy; and 
no deep-seated infection (uncomplicated SAB). ≥ 28 days for all other patients 
(complicated SAB). 
o Semi-appropriate: 10–13 days for uncomplicated SAB; 24-27 days for 
complicated SAB. 
o Inappropriate: < 10 days for uncomplicated SAB; < 24 days for complicated SAB.  
▪ Overall definitive antibiotic management 
o Optimal: both choice and duration appropriate 
o Suboptimal: either choice or duration semi-appropriate 
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Relapse: A new positive blood culture for S. aureus ≥ 30 days after a previously sterile blood 
culture, in a patient who had previously received therapy (any antibiotic or duration) for 
confirmed SAB. 
4.2 Study design 
This study is an analysis of a prospective observational study nested within an existing clinical 
registry in the Division of Infectious Diseases and HIV Medicine (the Division) at Groote Schuur 
Hospital. The registry and the nested study have prior ethics approval (HREC R004/2012 and 
HREC 643/2015).  
4.3 Setting 
The data used for this analysis are from inpatients at GSH, a tertiary referral hospital in the 
Western Cape province. This hospital serves the Cape metropolitan area, and is the primary 
teaching hospital associated with the University of Cape Town. GSH also receives direct referrals 
from clinics within its designated drainage area, and for these patients the hospital serves as a 
secondary level centre. The hospital includes all major medical and surgical divisions with a total 
of 893 beds, and has over 40 000 admissions and 21 000 operations per annum. GSH has an on-
site diagnostic microbiology laboratory with 3 full-time clinical microbiologists on staff. Results 
of all significant blood culture isolates (including S. aureus) and antibiotic susceptibility data are 
communicated directly to the requesting physician by phone. All results are also immediately 
available on the online hospital laboratory results system. However, the finding of gram positive 
cocci in a positive blood culture is not routinely called out because of high contamination rates 
with coagulase negative staphylococci.  
4.4 Population and sampling 
The patient population of GSH is mainly from urban and peri-urban areas, including townships, 
with a low to middle socio-economic status, and a high burden of HIV and related infections, 
largely tuberculosis. The clinical details of all inpatient consultations performed by the Division 
at GSH are recorded in a registry which was set up in 2009, and which currently contains almost 
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patients at GSH with an episode of SAB would be seen by either an infectious diseases specialist 
or senior registrar. An electronic notification system was set up to facilitate this, whereby the 
results of all blood cultures positive for S. aureus at GSH are automatically sent via email to a 
member of the Division. The patient is then seen within 36 hours of notification. In addition to 
this notification, a comment was placed beneath all electronic laboratory reports of SAB 
episodes detailing the recommended therapy and encouraging referral to Infectious Diseases. 
This analysis will include the first 100 consecutive distinct SAB infection episodes since the start 
of the new Divisional policy (November 2013). 
Inclusion criteria 
▪ Age > 13 years 
▪ Isolation of S. aureus from ≥ 1 blood culture, regardless of clinical evidence of systemic 
infection (ie. All positive cultures are considered to represent true bacteraemia) 
▪ Single isolate (not mixed with another organism) 
▪ Inpatient at GSH (even if the culture was performed elsewhere) 
▪ A new infection episode is defined as a positive blood culture for S. aureus ≥ 30 days 
after a previously sterile blood culture 
4.5 Research procedures and data collection methods 
A separate clinical data collection form (in addition to the entry in the general registry) was 
designed for the purpose of this study (appendix A). Patients with SAB were followed by a 
member of the Division after the initial consult for the duration of the admission, routinely 
collected clinical information was entered onto hardcopy data collection forms. 90-day 
outcome data was obtained using Clinicom, the Provincial digital clinical record system. 
The following variables were collected for each patient with SAB and captured on a specifically 
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▪ Medical comorbidities 
o Including specific risk factors for SAB: diabetes, renal disease, alcoholism, HIV 
infection, presence of active drip-site infection, presence of an endovascular or 
intra-articular prosthetic material 
o Presenting clinical problem 
o Clinical evidence of endocarditis: presence of new murmur with or without 
peripheral immunological or embolic signs 
▪ Microbiological factors 
o Incubation time 
o MSSA or MRSA 
o Vancomycin minimum inhibitory concentration (MIC) (for MRSA isolates) 
o Antibiogram of the isolate 
o Time to notification of the clinician by the laboratory (time between initial blood 
culture and notification) 
▪ Management 
o Timing of initial blood culture after admission 
o Timing and number of repeat blood cultures performed (after empiric and 
definitive therapy) 
o Timing and choice of empiric and definitive therapy 
o Dose of vancomycin: use of loading dose; timing and value of trough 
concentration 
o Use of source control (if indicated) 
o Use of echocardiography: modality, timing and findings 
▪ Outcomes 
o Complications of therapy and hospital stay 
o Duration of hospital stay 
o Relapse 
o Mortality: inpatients and 90 days 




 Part A. Research Protocol 
4.6 Statistical analysis 
Anonymised data captured in Microsoft Excel (2013) spreadsheets will be cleaned and analysed 
using R (R Core Team (2016). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria.).  Descriptive statistics will be used to 
describe and summarise the data obtained from the study. Normality of data will be assessed 
using histograms and the Shapiro Wilk test. Kaplan-Meier estimates will be used to describe 
inpatient survival and time to initiation of antibiotics. Multivariable logistic regression with a 
priori variables identified from the literature will be used to identify factors associated with 
complicated infection and 90-day mortality. Decisions regarding inclusion of variables in the 
final model will be based on their effect size on the outcomes of interest. Pictures, graphs, or 
charts will be used to visually display data. For all statistical tests, a p-value ≤ 0.05 will be 
considered significant. The specific statistical tests used to address each objective are displayed 
in Table 1. The data tables used to organise and categorise data are displayed in Tables 2-5. 
4.7 Statistical power 
From the literature 90-day mortality is hypothesised to be approximately 25% or higher, as a 
result of the relatively higher HIV prevalence in our sample. With a study population of 100 
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Table 1: Statistical analysis of objectives 
Question Null hypothesis Statistical test 
Objective 1 
What are the demographics, clinical 
characteristics and microbiological 
profile of South African patients with 
SAB? 
NA Descriptive statistics: Categorical variables will be summarized 
using proportions. If the expected frequencies of all cells in the 
table are 1 or greater, and no more than 20% of the cells have 
an expected frequency less than 5, the chi-squared tests will be 
used to compare proportions. If the assumptions for expected 
frequencies are not met, the Fischer’s exact test will be used. 
Continuous variables (age) will be assessed for normality using 
histograms and the Shapiro-Wilk test, and groups compared 
using t-test if the data are  normally distributed, and a paired 
Wilcoxon signed rank test if not. 
Objective 2 
What clinical profile and risk factors of 
SAB patients are associated with the 
individual outcomes of both inpatient 
and 90-day mortality, complicated 




There is no association between HCA 
vs CA SAB and the resistance pattern 
of the infecting organism and the 
individual outcomes of both 
inpatient and 90-day mortality, 






Descriptive statistics as described above. 
Survival analysis: Kaplan-Meier estimate and 
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Objective 3 
What proportion of SAB patients 
receive adequate antibiotic therapy, 
including choice of agent and duration 
of therapy, comparing MSSA-B and 
MRSA-B? 
There is no association between the 
resistance profile of the infecting 
organism and antibiotic 
management. 
Descriptive statistics as described above. 
What is the probability of receiving 
definitive antibiotic therapy by a 
certain point in time, comparing 
MSSA-B and MRSA-B? 
There is no association between 
MRSA-B and the time to definitive 
antibiotic therapy. 
Survival analysis: Kaplan-Meier estimate and 
Cox proportional hazards model 
What are the characteristics of 
patients who underwent 
echocardiography, and is there a 
relationship with the diagnostic yield 
and findings? 
There is no association between the 
presence of clinical endocarditis, 
prosthetic material and CA-SAB and 
a positive echocardiography finding. 
Descriptive statistics as described above. 
Objective 4 
What is the relationship between 
patient and treatment-related factors 
and complicated SAB and mortality? 
There is no relationship between 
patient and treatment-related 
factors and complicated SAB and 
mortality. 
Univariate and multivariate logistic regression analysis.  
A priori variables: age, sex, cloxacillin resistance, CA vs HCA 
infection, presence of a comorbidity, adequacy of AB therapy, 
and time to initiation of definitive therapy. 
Other variables to be considered: vancomycin MIC and timing to 
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Table 2: Data table for objective 1. a) General patient characteristics. 







OR (95% CI) P-value 
Age (years) 
Mean (±SD) 
>60, no. (%) 
    
Male, no. (%)     
Co-morbidities 
   HIV positive 
   Diabetes mellitus 
   Renal failure 
   Cardiac disease 
    
MRSA     
Source of infection 
   Drip site definite 
   Drip site probable 
   SSTI 
   Central line 
   Dialysis catheter 
   Pneumonia 
   Surgical wound 
   UTI 
   Other 
    
Drip site sepsis     
Metastatic foci     
OR = odds ratio; CI = confidence interval; MRSA = methicillin-resistant staphylococcus aureus; SSTI = skin and 




 Part A. Research Protocol 
Table 3: Data table for objective 2. a) Inpatient outcomes, and b) 90-day outcomes. 
a) Inpatient Outcomes 
  Mortality Complicated Infection 
Relapse Uncomplicated Total SAB-
related 




Age <60                 
≥60                 
Sex Female                 
Male                 
Any 
comorbidities 
Yes                 
No                 
HIV+ Yes                 
No                 
Renal failure Yes                 
No                 
CVS disease Yes                 
No                 
Organism MSSA                 
MRSA                 
 
b)  90-day Outcomes 
  Mortality Complicated Infection 
Relapse Uncomplicated Total SAB-
related 




Age <60                 
≥60                 
Sex Female                 
Male                 
Any 
comorbidities 
Yes                 
No                 
HIV+ Yes                 
No                 
Renal failure Yes                 
No                 
CVS disease Yes                 
No                 
Organism MSSA                 
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Table 4: Data tables for objective 3. a) Adequacy of antibiotic therapy, b) Time to definitive 
antibiotic therapy, and c) Echocardiography patient characteristics and findings. 
a) Antibiotic therapy 
  Organism 
Total 
MSSA MRSA 
Choice of empiric AB agent Adequate    
Inadequate    
Choice of definitive AB agent Appropriate    
Inappropriate    
Duration Appropriate    
Semi-
appropriate 
   
Inappropriate    
Overall definitive management Optimal    
Suboptimal    
Inadequate       
b) Time to definitive antibiotic therapy 











N    
Mean     
SD     
P25     
P50     
P75     
IQR     
Min     
Max     
c) Echocardiography 
 Result  Total 
Positive Negative 
Clinical endocarditis Yes    
No    
Prosthetic material Yes    
No    
CA vs HCA CA    
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Table 5: Data table for objective 4. a) Univariate logistic regression model output, and b) 
Multivariate logistic regression model output. 
Covariate a) Univariate model b) Multivariate model 









      
Any comobidities (ref=no)      
HIV (ref=no) 
     
Renal failure (ref=no) 
     
Female sex (ref=male) 
     
MRSA (ref=MSSA) 
     
CA (ref=HCA) 
     
Adequacy of definitive AB therapy 
(ref=optimal) 
     
Suboptimal 
     
Inadequate 
     
Time to initiation of definitive 
therapy 
     
Timing to notification of results 
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5.  Ethical considerations 
This study aims to abide by the ethical principles of health research that include justice, 
beneficence, and autonomy. This study will seek ethical approval from University of Cape Town 
Human Research Ethics Committee (HREC) before proceeding. 
Benefits of study 
This study aims to describe the management and outcomes of SAB in a local setting, and the 
information gained through the study may contribute to improving the care of patients with 
this condition. Individually, participants may have potentially benefitted from inclusion because 
of more intensive involvement of infectious diseases physicians in their care. 
Risks of study 
The data collected for this analysis is part of routine patient management, and will therefore 
have no impact on the clinical care of included subjects. Patient identifiers will only be 
accessible to the named investigators and will be removed from data entered into the electronic 
database. Thus, the potential harm for study subjects will be minimal and not clinical in nature, 
thus adhering to the ethical principle of non-maleficence. 
Informed consent process 
The analysis makes uses of data collected for an existing clinical registry which has been 
exempted from the requirement of informed consent (HREC R004/2012).  Additional data 
collected especially for this study is included in this exemption. 
Privacy and confidentiality 
Patient names will not be included in the electronic dataset used for the final analysis. Data 
from hardcopy extraction sheets will be transferred to and stored in a dedicated, password-
protected Excel spreadsheet created specifically for the proposed study. Only the named 
investigators will have access to this database. Data extraction sheets will be filed and stored in 
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Dissemination of study results 
Results of this study will be made available and accessible to researchers in the field of 
infectious disease by publishing results in the form of a manuscript in a peer-reviewed journal 
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6.  Study limitations 
As the study design is relying on data collected by clinicians during patient care, it relies on the 
accuracy and completeness of data. The relatively small sample size will limit the statistical 
power of the study. Additional involvement of ID clinicians in the care of patients with SAB as 
a part of the study could bias results leading to improved outcomes. This could limit the 
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7.  Study significance 
 
An improved awareness of the management and outcomes of SAB cases in a local South African 
setting has several potentially significant benefits. The main implication is contributing more 
knowledge about this disease in our setting, and understanding practice and risk factors that 
could improve future management. Improved local knowledge about SAB can be useful in 
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1.  Introduction 
Staphylococcus aureus is a major human pathogen found worldwide, causing a wide range of 
clinical infections from skin and soft tissue infections to life-threatening invasive disease. A 
severe manifestation is S. aureus bacteraemia (SAB), a common cause of both community- 
and hospital-acquired infections. Multiple studies have documented the prevalence and 
outcomes of SAB in high income countries (HIC), however there remains a paucity of 
knowledge regarding SAB in low and middle-income countries (LMIC). This information is 
needed to inform risk stratification and identify areas for improvement in case management. 
A global concern is also the lack of high-quality evidence to guide the management of SAB.  
2.  Aims and Objectives 
This literature review aims to synthesise and appraise the current literature regarding SAB 
epidemiology, treatment and outcomes, with the aim to place this research study within 
context and identify gaps in research. 
The specific review objectives are to report the following items and identify needs for 
further research: 
1. The prevalence and clinical burden of SAB 
2. Risk factors for acquiring SAB 
3. The role of antibiotic-resistant S. aureus in SAB 
4. Clinical manifestations and outcomes of SAB 
5. Management of SAB 
6. SAB in LMIC, particularly Sub-Saharan Africa 
3. Search Strategy 
Literature was sourced using PubMed (https://www.ncbi.nlm.nih.gov/pubmed/), Google 
Scholar (https://scholar.google.co.za/) and the Cochrane library 
(http://www.cochranelibrary.com/). Medical Subject Heading (MeSH) terms were used to 
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search Pubmed as a primary source of literature. Google Scholar and the Cochrane Library 
were use as secondary sources to identify and explore any further articles. 
The search terms used across all three databases were similar and focussed on the 
same themes. The first theme was the epidemiology of SAB, both worldwide and in Sub-
Saharan Africa. This included specific mentions of prevalence, risk factors and outcomes. The 
second theme was the management and treatment of SAB, both worldwide and in Sub-
Saharan Africa. The third theme was SAB caused specifically by methicillin-resistant S. aureus 
(MRSA). The specific search terms and strategies are shown in Table 1. 
Table 6 Summary of search strategy employed for this literature review 
1. PubMed 
Theme Search terms Search Strategy 




risk factors and Africa 
“Staphylococcus aureus bacteraemia”[MeSH] AND 
(“epidemiology”[MeSH] OR “prevalence”[All Fields] OR 
“mortality”[All Fields] OR “risk factors”[All Fields”]) AND 
(“Africa”[MeSH] OR “”South Africa”[All Fields] OR “Sub-
Saharan Africa”[All Fields] OR “low-income 
countries”[All Fields] OR “low-middle income 
countries”[All Fields]) 
Management of SAB Staphylococcus aureus 
bacteraemia and 
management 
(“Staphylococcus aureus bacteraemia”[MeSH]) AND 
(“management”[MeSH] OR “treatment”{All Fields] OR 







“Methicillin-resistant Staphylococcus aureus 
bacteraemia”[MeSH] OR “resistant Staphylococcus 
aureus bacteraemia”[MeSH] OR “MRSA 
bacteraemia”[All Fields] 
2. Google Scholar 




risk factors and Africa 
Staphylococcus aureus bacteraemia AND (epidemiology 
OR prevalence OR mortality OR risk factors) AND (South 
Africa OR Africa OR Sub-Saharan Africa OR low-income 
countries OR low-middle income countries) 
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Management of SAB Staphylococcus aureus 
bacteraemia and 
management 
Staphylococcus aureus bacteraemia AND (management 







Methicillin-resistant Staphylococcus aureus 
bacteraemia 
3. Cochrane Library 
Management of SAB Staphylococcus aureus 
bacteraemia and 
management 
Staphylococcus aureus bacteraemia and management 
 
3.1 Inclusion criteria 
▪ All published articles written in English. This review was not limited to studies from 
LMIC as the amount of research from these areas is limited, however papers from 
Sub-Saharan Africa and other LMICs were given priority, with key papers cited from 
other regions. 
▪ The measures reported included prevalence, risk factors, complicated infection and 
mortality. 
▪ Experimental and observational studies were included in this review. More recent 
studies (published in the past 10 years [2007 to 2017]) were given priority, as were 
reviews, very large cohorts and multi-centre studies. 
▪ The bibliographies of all the literature that met the inclusion criteria were further 
examined based on the inclusion criteria used for the initial literature search from in 
PubMed and Google Scholar.  
3.2 Exclusion criteria 
▪ Studies reporting on outcomes within highly specified patient groups e.g. 








In higher income regions, defined as having a gross national income of $12 236 or more per 
capita (World Bank Group 2018), the population incidence of SAB ranges from 10 to 30 per 
100 000 person-years, with S. aureus being the second most common cause of bloodstream 
infections (Laupland et al. 2013). Large geographical discrepancies in SAB incidence likely 
reflect differences in health care systems, infection control practices, and the completeness 
of surveillance data (Van Hal et al. 2012). Healthcare-associated SAB (HCA-SAB) is associated 
with higher mortality, longer length of stay, and greater total hospital costs compared to 
bacteraemia of any other cause in the United States (US) (Shorr et al. 2006). 
Far less is known about the incidence and impact of SAB in relatively lower income 
regions such as Sub-Saharan African. It is likely comparable to high income nations, and may 
be higher due to the influence of HIV (Larsen et al. 2012). In a systematic review of 22 studies 
reporting causes of  bloodstream infections from more than ten countries on the African 
continent, the overall prevalence of SAB amongst adult patients admitted with bloodstream 
infections was 5.4% (111 of 2078 isolates) (Reddy et al. 2010). This study was limited in that 
hospital-based cohorts were used to describe community-acquired infections, which may 
have restricted inclusion to those with more severe disease or those who had access to 
healthcare facilities, resulting in falsely lowered estimates of non-malaria bloodstream 
infections. Included studies spanned a period of more than 20 years, and therefore acted 
more as a guide of the range of pathogens causing bloodstream infections, rather than as a 
reference of current prevalence levels.  
A recent cross-sectional study using passive laboratory surveillance of routine clinical 
cultures from three state hospitals in Gauteng Province, South Africa, showed an SAB 
incidence of 1.9 to 3.7 cases per 1000 admissions (Smidt et al. 2015). The proportions of 
healthcare-associated and community-associated SAB were not reported. At Groote Schuur 
Hospital (GSH), a state hospital in Cape Town, South Africa, an informal review of blood 
cultures in 2014 showed that over 12 months SAB accounted for 232 of 2 222 (10.4%) positive 
cultures, and was the second most common pathogen recovered after coagulase-negative 
staphylococci (Tina Wojno, personal communication). Longitudinal population-based studies 
are needed to more accurately determine the burden of S. aureus in lower income nations. 
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Table 7 Summary of key studies included on epidemiology of SAB. 




City and country Study design Sample size; 
Median age 
(IQR)  
Aim Key findings 
Larsen et 
al 




To assess incident rates of SAB in HIV-infected 
population in era of ART 
Among HIV-infected individuals, a 
latest CD4 count less than 100 
cells/mL was the strongest 











18 430; not 
specified 
To define the occurrence of all MSSA and MRSA-
bacteraemia within a large multinational population 
and to evaluate temporal and regional differences 
Annual incidence 26.1/100 000 
population; incidence rates of 
hospital-onset MSSA community-
onset MRSA and hospital-onset 













To study the epidemiology of the leading causes of 
BSI in Africa 
531 (9.5%) of non-malarial BSI were 
due to Staphylococcus aureus.  
Shorr et 
al 











To review the predictors of mortality in SAB Incidence rates vary from 19 to 
50/100 000 population; age most 
consistent predictor of mortality. 
        
Note: Studies from South Africa are included in a separate table. ART = antiretroviral therapy; BSI = bloodstream infection; HCA = healthcare-associated; IQR = inter-quartile range; HIV = 
human immunodeficiency virus; MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteraemia; SD = standard deviation. 
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5. Risk factors 
Various patient factors affect the risk of developing SAB, with the most important of these 
being the presence of intravascular foreign material, such as peripheral or central intravenous 
catheters (Jensen et al. 1999; Bassetti et al. 2011), as well as the presence of other prosthetic 
material, such as joints or heart valves (Forsblom et al. 2011). 
Extremes in age have also been shown to be associated with increased SAB incidence. 
Various studies have shown high rates in the first few years of life, a low incidence in young 
adulthood, and a gradual rise in incidence with advancing age (Laupland & Church 2014; 
Allard et al. 2008; Asgeirsson et al. 2011; Huggan et al. 2010). In a South African study, the 
greatest proportion of SAB occurred in those aged <5 years (Smidt et al. 2015). SAB is also 
more commonly found amongst males, with a male to female ratio of 3:2 (Allard et al. 2008; 
Klevens et al. 2007; Asgeirsson et al. 2011; Huggan et al. 2010). However a cohort study in 
Denmark showed that female patients with community-acquired SAB (CA-SAB) experienced 
an increased 30-day mortality compared with male patients (Smit et al. 2017), suggesting that 
sex should be considered in the triage and risk stratification of CA-SAB patients. Ethnicity is 
also associated with different incidences of SAB, with higher incidences on non-white 
populations (Klevens et al. 2007; Johnson et al. 2005; Cookson et al. 2012).  
People living with HIV (PLWH) have a significantly increased incidence of SAB (Larsen 
et al. 2012; Wilson et al. 2008). While some of this increase is related to higher rates of 
intravenous drug use amongst PLWH, SAB incidence is still increased amongst the non-
injection drug-using HIV-infected population (Wilson et al. 2008), in whom lower CD4 cell 
counts have been independently associated with SAB. Men who have sex with men (MSM) 
have higher rates of HCA-SAB (Wilson et al. 2008). Intravenous drug use is a major risk factor 
for SAB in all groups, independent of HIV status (Spijkerman et al. 1996; Palepu et al. 2001; 
Tuazon & Sheagren 1974). In South Africa, HIV infection is associated with a greater incidence 
of SAB in children (Groome et al. 2012). 
Patients receiving haemodialysis are at  greater  risk of SAB (Kallen et al. 2010; 
Fitzgerald et al. 2017). The main factor responsible for this increased risk is the presence of 
an intravascular access device (Fitzgerald et al. 2017). Other host factors amongst dialysis 
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patients, such as neutrophil dysfunction, iron overload, diabetes, and increased rates of 
colonisation (Zimakoff et al. 1996), contribute to an impairment in host immunity and thus 
increase the likelihood of invasive S. aureus infections. Dialysis can also affect plasma 
concentrations of antibiotics, thus potentially decreasing their efficacy and increasing the risk 
for relapsing SAB (Jeremiah et al. 2014; Vandecasteele & Vriese 2011). 
 6. Methicillin-resistant S. aureus 
The development of methicillin resistance in S. aureus is associated with increases in 
mortality, morbidity, length of hospitalisation and cost of health care (Cosgrove 2006). The 
contribution of MRSA to SAB has varied globally, with recent reductions shown in some high 
income nations (Johnson et al. 2012; Cookson et al. 2012; Kallen et al. 2010; Jarvie et al. 2008; 
Jarlier et al. 2010), likely linked to improvements in infection control procedures. MRSA in the 
US is largely community-acquired and caused by a single clone, USA300. Molecular 
epidemiology of South African strains suggests that this clone is largely absent, and most 
MRSA is HCA (Goering et al. 2008). A long-term study in Malawi showed an increase of 
methicillin resistance in SAB infections from 7.7% of infections in 1998 to 18.4% in 2016 
(Musicha et al. 2017). In South Africa, the prevalence of S. aureus infections that showed 
methicillin resistance was approximately 24% between 2007 and 2011 in state sector 
hospitals (Naidoo et al. 2013; Perovic et al. 2006), and over 30% in private institutions (Brink 
et al. 2007). In 2015, reported MRSA levels had increased to 36% (Smidt et al. 2015). 
Approximately 50% of 63 HCA S. aureus bloodstream isolates isolated from patients were 
resistant to cloxacillin at GSH in Cape Town (Mckay & Bamford 2015).  
In a recent local study of 365 SAB cases amongst children, MRSA was responsible for 
26% of community-acquired SAB and 72% of nosocomial infections (Naidoo et al. 2013). 
Infants, children with malnutrition, and residents of long-term care facilities were at highest 
risk for MRSA bacteraemia (Naidoo et al. 2013). The study was retrospective in nature, and 
may have been biased by non-standardised indications for blood culture, variability in blood 
culture volumes collected, and the initiation of antibiotics prior to blood culture collection in 
some cases. One study has shown HIV infection to be a predictor for MRSA infection in the 
South African setting (Smidt et al. 2015), however 50% of the isolates from one of the 
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hospitals in the study were not tested for antibiotic susceptibility, which may have biased the 
results. There was also a large amount of missing data surrounding HIV status and CD4 count. 
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 Table 3 Summary of key studies included on risk factors for SAB.  






Study design Sample size; 
Median age 
(IQR)  













To examine changes in the incidence and mortality 
associated with SAB before and after the emergence 
of MRSA 
Incidence of MSSA-B stable, incidence of 
MRSA-B increased from 0 to 7.4/100 000 
population. 
Asgeirss
on et al 




To analyse changes in the incidence and mortality of 
adult SAB in Iceland 
Incidence rose from 22.7 to 28.9 per 100 
000 per year during the period. 
Bassetti 
et al 
2011 Jan 207 – 
Dec 2007 




To explore epidemiological characteristics and 
predisposing risk factors associated with HCA and CA 
SAB, and to evaluate any differences in mortality and 
efficacy of initial antimicrobial therapy on treatment 
outcome 
Risk factors for HCA: renal failure, previous 
hospitalisation or antibiotics. Septic shock, 
MRSA and inadequate antimicrobial 












To evaluate the impact of the Cleanyourhands 
campaign on SAB incidence 
Rates fell for MRSA bacteraemia (1.88 to 
0.91 cases per 10 000 bed days). 
Fitzgeral
d et al 








To review the changing incidence of SAB in 
haemodialysis patients 
Overall rate of SAB was 17.9 per 100 
patient-years. The rate of MRSA - was 5.6 
per 100 patient-years. 
Forsblom 
et al 




To compare predisposing factors, disease progression 
and outcome of HCA- and CA-SAB 
54% were HCA. HCA associated with 
permanent foreign body; deep infection, 
no infection focus. 
Huggan 
et al 






To describe longitudinal incidence of SAB in a region of 
New Zealand with low MRSA prevalence 
Crude incidence of S. aureus bacteraemia 








21 503; not 
specified 
To describe changes in rates of invasive health 
care−associated MRSA infections from 2005 through 
2008 among residents of 9 US metropolitan areas 
Incidence of HCA community-onset 
infections was 2.20 per 10 000 population 
in 2005 and decreased 5.7% per year. 
Wilson 
et al 




4 607; not 
specified 
To define the incidence and risk factors for methicillin 
resistant Staphylococcus aureus (MRSA) bacteraemia 
in an HIV-infected population 
Incidence 19.6 cases per 1000 person-
years. Risk factors injection-drug use; 
renal disease and CD4 <200cells/mL. 
Note: studies included in tables from previous sections are not repeated.  Studies from South Africa are included in a separate table. HCA = healthcare-associated; IQR = inter-quartile range; 
HIV = human immunodeficiency virus; MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteraemia. 
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Table 4 Summary of key studies included on MRSA. 
 




City and country Study design Sample size; 
Median age 
(IQR)  
Aim Key findings 
Goering 
et al 









To determine the genetic characteristics of 
Staphylococcus aureus 
The most common MRSA clone had 
sequence type 8: USA300. This 
clone was isolated exclusively in 














To describe the distribution of organisms and of 
antibiotic susceptibility among isolates from blood 
cultures at a tertiary academic hospital, stratifying 
by place of infection acquisition. 
Nearly three-quarters of infections 
were healthcare acquired. All CA 
SAB isolates v. 52.4% of HCA 





2010 1993-2007 Paris, France Prospective 
observational 
NA To determine the effect of a long-term infection 
prevention initiative on MRSA rates 
There was a significant progressive 
decrease in MRSA burden (−35%) 




2010 2005-2008 United States Prospective 
observational 
21 503, not 
specified 
To describe changes in rates of invasive health 
care−associated MRSA infections from 2005 through 
2008 among residents of 9 US metropolitan areas 
The incidence rate of hospital-
onset invasive MRSA infections was 
1.02 per 10 000 population in 2005 
and decreased 9.4% per year. 
 
Musicha 
et al  
2017 1998-2016 Malawi Surveillance 
study 
29 183 To report long-term trends in bloodstream infection 
and antimicrobial resistance 
MRSA was first reported in 1998 at 
7·7% and represented 18·4% of S 
aureus isolates in 2016. 
Note: studies included in tables from previous sections are not repeated. Studies from South Africa are included in a separate table. HCA = healthcare-associated; IQR = inter-quartile range; 
MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteraemia. 
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7. Clinical manifestations and outcomes 
The presence of various primary clinical foci for SAB may be identified, with common sources 
being vascular catheter-related infections, skin and soft tissue infections, pleuropulmonary 
infections, osteoarticular infections and infective endocarditis (IE) (Laupland et al. 2008; 
Bishara et al. 2012; Bassetti et al. 2011; Turnidge et al. 2009; Kaasch et al. 2014; Van Hal et al. 
2012). In many cases a source of infection is not found, and is  associated with worse 
outcomes than infection sources such as intravenous and urinary tract catheters (Van Hal et 
al. 2012). 
SAB can be classified as “complicated” or “uncomplicated”. This designation has 
important implications for investigations, duration of antibiotic treatment, and overall 
prognosis. A key  The following criteria have been used to define uncomplicated SAB: (i) 
exclusion of IE by echocardiography, (ii) no implanted prostheses, (iii) negative results of 
follow-up blood cultures drawn 2 to 4 days after the initial set, (iv) defervescence within 72 
hours (h) after the initiation of effective antibiotic therapy, and (v) no evidence of metastatic 
infection (Fowler et al. 2003). Any other patient should be considered to have complicated 
SAB. In a prospective, observational cohort study of 724 patients with SAB in the US, 
complicated infection was present in over 40% of cases (Fowler et al. 2003). Establishing the 
status of individual patients regarding each of these criteria allows appropriate decisions to 
be made about subsequent treatment duration. Failure of identification of complications can 
lead to relapsing bacteraemia and poor outcomes (Fowler et al. 2003).  
A pooled analysis of 3 395 adult patients with SAB in centres in Germany, Spain, the 
UK and the US showed a crude 90-day mortality of 29.2% (Kaasch et al. 2014), increased in 
cases of HCA and MRSA infection. However only tertiary care patients were included, and 
limited data were available describing disease comorbidities and disease severity at SAB 
onset. A UK study of 724 adult patients reported a mortality of 29.0%, varying according to 
organism-related factors, such as the presence of cloxacillin resistance (Fowler et al. 2003). A 
lack of improvement in patient outcomes could reflect both a relative decrease in antibiotic 
efficacy and larger numbers of older, “sicker” patients that now acquire SAB (Tong et al. 
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Predictors of mortality from SAB include increasing age, the presence of co-morbid 
conditions, the absence of an identifiable source, extent, and persistence of infection, initial 
inadequate antibiotic treatment, and failure to achieve source control (Bassetti et al., 2011; 
Braquet et al., 2016; Turnidge et al., 2009). Several studies have also shown infection with 
MRSA to be an independent risk factor for mortality in SAB (Cosgrove 2006; Naidoo et al. 
2013). Delayed initiation of optimal antibiotic therapy by two days has been shown to more 
than double the risk of mortality (Marchaim et al. 2010; Lodise et al. 2003). 
While HIV is associated with an increased risk of HIV acquisition, its effect on mortality 
remains uncertain. Several studies have reported no increase in mortality (Perovic et al., 2006; 
Senthilkumar et al., 2001). A more recent case-control study in Denmark showed an increased 
30-day mortality rate (OR 11.9; 95% 2.2 to 65.9) in PLWH (Jaliff et al., 2014), however the 
retrospective design and small sample size of this study may have limited its validity, and HIV-
related factors such as CD4 count, antiretroviral therapy and viral load were not associated 
with increased mortality. This may suggest that it is increased interaction with healthcare 
services and subsequent exposure to S. aureus via venous cannulation, resulting in increased 
rates of re-infection, which may be contributing more to the increased mortality rather than 
HIV infection itself. 
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Table 5 Summary of key studies included on SAB outcomes. 












Aim Key findings 
Bishara 






ive cohort  
1347; not 
specified 
To analyse clinical features and outcomes of 
patients with HCA SAB. 
Mortality at 30 days was 40.2% (507/1261) and at 1 year was 
63.4% (800/1261).  
Braque








To identify prognostic factors in a large 
prospective cohort of SAB patients and to 
analyse the impact of first-line anti- biotics on 
case-fatality. 
Week 12 case-fatality rate was 671/1972 (34.0%). Main 
prognostic factors: age, septic shock, unknown primary focus, 
metastatic cancer.  Initiating empiric antibiotics with 
antistaphylococcal penicillins or vancomycin may be associated 












To define readily available clinical 
characteristics that could help identify 
patients at risk for complicated SAB. 
Complicated SAB was present in 43% of 724 consecutive adult 
hospitalized patients.  A scoring system based on the presence 
or absence of 4 risk accurately identified complicated SAB. 
Kaasch 












To describe how its clinical presentation 
varies between populations and to identify 
common determinants of outcome. 
Crude 14 and 90-day mortality was 14.6% and 29.2%, 
respectively. Age, MRSA bacteraemia, nosocomial acquisition, 
endocarditis, and pneumonia were independently associated 
with death, but a strong association was with an unidentified 
infective focus. 
Laupla
nd et al  




















to determine the effect of delayed therapy on 
morbidity and mortality associated with 
nosocomial SAB 
Delayed treatment is independent predictor of infection-
related mortality (odds ratio, 3.8; 95% confidence interval, 1.3–











To determine association of risk factors with 
SAB mortality 
Delayed appropriate antibiotic therapy was significantly 












To describe the epidemiology, 
pathophysiology, clinical manifestations, and 
management of S. aureus infections. 
Predictors of mortality include: age, co-morbidities, source and 
extent of infection. 
Turnid









To document the types of, and mortality 
from, SAB in Australia and New Zealand, and 
determine factors associated with mortality 
Independent predictors of mortality were age, sepsis 
syndrome, pneumonia, a secondary focus, endocarditis. 
Note: studies included in tables from previous sections are not repeated.  Studies from South Africa are included in a separate table. HCA = healthcare-associated; IQR = inter-quartile range; 
MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteraemia; SD = standard deviation. 
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Both US and United Kingdom guidelines for the management of MRSA-bacteraemia (MRSA-
B) are available, and recommend a minimum of 2 weeks intravenous therapy for patients with 
uncomplicated SAB, and longer-term (4–6 weeks) intravenous antibiotic therapy for those 
with complicated infections (Liu et al. 2011; Gemmell et al. 2006). Evidence to support various 
recommendations is largely considered to be of a poor quality. Only a single small randomised 
control trial (RCT) has been performed to examine the optimal duration of antibiotic therapy 
for any form of SAB, and reported insufficient data to allow conclusions regarding the optimal 
duration of therapy for patients with or without endocarditis (Rahal 1986). 
The South African Antibiotic Stewardship Programme (SAASP) has developed an 
antibiotic prescribing guideline based on currently available evidence, including an algorithm 
for the treatment of SAB (Wasserman et al. 2014). A minimum of 4 weeks antibiotic therapy 
is advised for patients with prosthetic heart valves or endocarditis, persistent bacteraemia or 
fever after 72 h of antibiotic therapy, or a non-removable or deep-seated site of infection, 
such as bone.  
The involvement of infectious diseases (ID) specialists is an important aspect of 
management. Recommended management strategies are carried out significantly more 
frequently among patients seen by an infectious diseases specialist, contributing to the 
survival benefit (Paulsen et al. 2015; Liu 2013; Vogel et al. 2016). A systematic review and 
meta-analysis of 18 reports showed a significant reduction in 30-day mortality in SAB patients 
seen by an ID consultant compared with those who did not have an ID consult (Vogel et al. 
2016), with a relative risk of 0.53 (95% CI 0.43-0.65). Follow-up blood cultures and 
echocardiography were also performed more frequently following ID consultation. Possible 
selection bias was present, as ID consultation was most likely selected for more severe disease 
and poorer prognosis, which decreased the likelihood of finding a positive effect. This bias 
was minimised by adjusting for patient and SAB baseline characteristics using multivariable 
modelling and propensity score matching. Potential confounding may also have been present 
in the fact that patients with better resources and those cared for in better resourced health 
facilities were more likely to see an ID specialist, thus biasing towards better outcomes. This 
was addressed using case matching within healthcare facilities. 
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Administration of appropriate antibiotic therapy has an important influence on the 
outcomes of both methicillin-sensitive S. aureus (MSSA) and MRSA (Van Hal et al. 2012). A 
meta-analysis of 6 studies demonstrated an almost two-fold survival benefit (OR, 1.84; 95% 
CI 1.25 to 2.71) for patients who received appropriate empiric therapy for MRSA-B (Paul et al. 
2010). In a cohort study of 1 896 patients with MSSA-bacteraemia (MSSA-B), first-line empiric 
antistaphylococcal penicillins (OR, 0.40; CI, 0.17-0.95) and vancomycin (OR, 0.37; CI, 0.17-
0.83), alone or combined with an aminoglycoside, were associated with improved mortality 
compared to other antibiotics (Braquet et al. 2016). Sterilisation of blood is achieved more 
rapidly with the use of beta-lactam drugs compared with vancomycin for MSSA-B (Khatib et 
al. 2009; Siegman-igra et al. 2005). There is also evidence that the use of vancomycin for SAB, 
regardless of beta lactam susceptibility, is an independent risk factor for recurrence and death 
(Mcconeghy et al. 2013; Johnson et al. 2003; Chang et al. 2003). Cephalosporins are 
frequently used for empiric therapy for hospitalised patients, but no comparative RCTs have 
been performed to evaluate the efficacy of cephalosporins for the treatment of MSSA-B. 
Limited observational data have shown favourable outcomes for cefazolin, but concerns exist 
about treatment failure in complicated SAB, particularly with the use of second and third 
generation cephalosporins (Thwaites et al. 2017). Another agent shown to have similar 
efficacy to standard therapy for both MSSA and MRSA bacteraemia in an RCT is the 
lipopeptide daptomycin (Fowler et al. 2006); however this drug is not available in the public 
sector in South Africa. Thus, the treatment of choice for SAB remains cloxacillin (or penicillin 
if susceptible) for MSSA and vancomycin for MRSA. 
One intervention in SAB management that is supported by high quality evidence is 
early source control, with surgical drainage of collections and removal of intravascular 
catheters (Thwaites et al. 2017).  
Imaging of the cardiac valves is performed in cases of SAB to determine if there is 
underlying IE present, however it is unresolved whether transoesophageal echocardiography 
(TOE) is required in all patients. The SAASP guidelines for SAB recommend echocardiography 
for the following patients: implanted prosthetic heart valves; clinical evidence of endocarditis; 
and community-acquired infection, which is associated with an increased risk of complicated 
SAB. TOE has an increased sensitivity for the detection of IE when compared to transthoracic 
echocardiography (TTE), however it is more expensive, less widely available, and is an invasive 
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procedure (Fowler et al. 1997; Hal et al. 2005; Khatib & Sharma 2013). The absence of clinical 
and microbiological features of complicated SAB have a good negative predictive value (93 to 
100%) for endocarditis, and may be used in these settings to identify low risk patients who do 
not require echocardiography (Holland et al. 2014). 
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Table 6 Summary of key studies on management of SAB. 
 




City and country Study design Sample size; 
Median age 
(IQR)  
Aim Key findings 
Fowler 
et al 
1997 1994-1996 United States Prospective 
cohort 
103; 56 
years (SD 15 
years)  
To examine the role of 
echocardiography in patients with SAB. 
IE is common among patients admitted to the 
hospital with SAB and is associated with an 








To review evidence of management 
strategies for SAB 
All adult patients with SAB should undergo 
echocardiography, unless identified with low-risk 
characteristics. Vancomycin and daptomycin are 










To assess whether consultation with 
infectious disease specialists 
decreased all-cause mortality or rate 
of complications of SAB 
 
Recommended management strategies were 
carried out significantly more often among 
patients seen by an infectious disease specialist.  
Rahal 1986 Unable to 
access 




To determine the role of antimicrobial 
therapy on SAB outcome. 
Data were insufficient to allow conclusions 
regarding the optimal duration of therapy for 












To describe the key principles for SAB 
management 
 
Early source control and long-term antimicrobial 
treatment for complicated infection are key. 
Vogel et 
al 
2016 Inception to 
May 2015 
Not specified Systematic 
review and 
meta-analysis 
5 377; not 
specified 
To evaluate the impact of infectious 
disease consultation on the 
management and outcomes of 
patients with SAB 
The appropriateness of antistaphylococcal agent 
and treatment duration was improved by 
infectious disease consultation; mortality was 
decreased; follow-up blood cultures and 
echocardiography performed more frequently. 
Note: studies included in tables from previous sections are not repeated.  Studies from South Africa are included in a separate table. IQR = inter-quartile range; MRSA = methicillin-resistant 
S. aureus; SAB = S. aureus bacteraemia; SD = standard deviation. 
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 9. Studies from South Africa 
Only five clinical studies of SAB have been conducted in South Africa (Table 2), three of which 
were retrospective in design and two of which focussed exclusively on children  (Smidt et al. 
2015; Naidoo et al. 2013; Perovic et al. 2006; Willcox et al. 1998; Groome et al. 2012). A 
prospective study of 113 consecutive episodes of CA-SAB was conducted at GSH over the 
years 1986 to 1991 (Willcox et al. 1998). Eleven percent of isolates were resistant to 
cloxacillin, and none of the patients were HIV-infected. The overall mortality was 35% at 3 
months, and complications occurred in 90% of patients, including endocarditis in 17%. 
Treatment was delayed by 24 h or more in 50% of all patients, and significantly more patients 
who died had received either inadequate or no antibiotic therapy compared to survivors.  
A recent prospective study was conducted across three Johannesburg public sector 
hospitals to describe the epidemiology of MRSA-B and factors associated with poor outcomes 
(Smidt et al. 2015). For unreported reasons, only 45% of all SAB episodes in the study period 
were included in the analysis, with a final study size of 240 isolates. The overall proportion of 
MRSA-B was 36%. The number of patients with complicated SAB was not reported, nor were 
the overall outcomes and choice and timing of antibiotic therapy.  
A retrospective review of SAB cases at two academic hospitals in Johannesburg, South 
Africa, reported on 449 episodes of SAB between 1999 and 2002 (Perovic et al. 2006). HCA 
infection was associated with an increased risk of MRSA-B. Intensive care unit admission and 
MRSA infection were strongly associated with increased mortality. Only 14-day mortality was 
studied, and antibiotic management was not assessed. 
A retrospective review of 161 cases of SAB in children hospitalised between 2005 and 
2006 at a tertiary state hospital in Johannesburg, South Africa (Groome et al. 2012), reported 
an incidence of 26 per 100 000 population per year, with 63 (39%) isolates identified as 
methicillin-resistant. Incidence was inversely related to age and greater in PLWH. Overall 
mortality was not reported. The retrospective design of the study, as well as the fact that 
children admitted to private hospitals or who had died in the community before seeking 
healthcare were not included, limited the accuracy of true SAB incidence. If the HIV status of 
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the child was unknown, they were assumed to be HIV negative, which may have resulted in 
misclassification bias.  
A separate retrospective study in children was carried out between 2007 and 2011 at 
a children’s hospital in Cape Town, South Africa (Naidoo et al. 2013). Over the study period, 
365 cases of SAB were identified, with an annual incidence of 3.28 cases per 1 000 hospital 
admissions. The overall case fatality rate was 8.8% over five years, with only MRSA infection 
identified as a significant risk factor for mortality. MRSA was responsible for 26% of SAB and 
72% of nosocomial infections. Again, this study is limited by its retrospective nature, resulting 
in a lack of standardisation of blood culture investigations and treatment protocols. 
10. Conclusion 
The predisposing factors and patient characteristics of SAB are well-described in HIC, however 
relatively little is known about SAB in the Southern African setting. Despite being a leading 
cause of bloodstream infections, there is a lack of quality evidence to guide the management 
of SAB. Previous studies have lacked standardisation and did not thoroughly evaluate 
treatment strategies. Because of the paucity of good quality data, the contemporary 
management and outcomes of SAB in South Africa is not well understood. The proposed study 
aims to address this knowledge gap by analysing prospectively collected clinical data of 
consecutive patients with SAB at a referral hospital in Cape Town, with the objectives of 
describing the South African patient profile of SAB, the antibiotic management, and the 
clinical and microbiological factors associated with poor outcome. 
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 Table 7 Summary of studies on SAB from South Africa. 
Author Year of 
publica
-tion 
Study period City and 
country 
Study design Sample size; 
Median age 
(IQR)  
Aim Key findings 
Groom
e et al 








days – 12.5 
years) 
To describe the burden of community-onset 
bacteraemic S. aureus infections in children in an area 
with a high prevalence of paediatric HIV infection, and 
to describe the antimicrobial resistance patterns. 
 
Incidence 26/100 000; MRSA 39% 









months (3.8 – 
42.3 months) 
To investigate the epidemiology 
of SAB at a single children’s hospital in South Africa 
over a five-year period, and to describe the incidence, 
clinical presentation, microbiologic profiles, risk 
factors, management and outcomes of children with 
both MSSA and MRSA bacteraemia. 
 
Incidence 3.28/1000 hospital 
admissions; MRSA 26% overall and 
72% of nosocomial infections; overall 
case fatality rate 8.8% over 5 years, 
with MRSA being the only significant 
risk factor for mortality.  
Perovic 
et al 
2006 November 1999 






years (SD 15.8 
years) 
To determine the number of patients presenting with 
SAB, to determine the proportion of MRSA versus 
MSSA infections, to determine the mortality rate of 
patients with SAB, to compare the mortality rate of 
MRSA versus MSSA SAB, and to identify risk factors 
associated with mortality. 
 
14-day mortality rate 23.2%; MRSA 
23.4% overall, MRSA infection 
associated with HCA infection and 
increased mortality intensive care unit 
admission associated with increased 
mortality. 
Smidt 









442; 29 years 
(0.4 – 45 
years) 
To describe the epidemiology of S. aureus bacteraemia 
and to determine factors associated with MRSA 
infection in South Africa. 
MRSA 36% overall; MRSA infection 
associated with recent hospitalisation, 
HIV infection and recent antibiotic use; 











113; 46 years 
(IQR not 
reported) 
To describe community-acquired S. aureus 
bacteraemia in a population where intravenous drug 
abuse is extremely uncommon. 
Mortality 35%; acute renal failure, 
shock and confusion associated with 
increased mortality; unknown infection 
focus in 58%. 
 
HCA = healthcare-associated; IQR = inter-quartile range; MSSA = methicillin-sensitive S. aureus; MRSA = methicillin-resistant S. aureus; SAB = S. aureus bacteraemia; SD = standard deviation. 
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The Management and Outcomes of Staphylococcus 
aureus Bacteraemia at a South African Referral 
Hospital: A Prospective Observational Study2 
ABSTRACT 
Objectives Limited evidence exists on the management and outcomes of Staphylococcus 
aureus bacteraemia (SAB) in resource-limited settings. The aim of this study was to describe 
a cohort of South African patients with SAB, and explore the factors associated with 
complicated infection and death.  
Method A prospective observational study of patients over the age of 13 years admitted to a 
South African referral hospital with SAB.  
Results One hundred SAB infection episodes occurring in 98 patients were included. SAB was 
healthcare-associated in 68.4%; 24.0% of all cases were caused by methicillin-resistant S. 
aureus (MRSA). Ninety-day mortality was 47.0%, with 83.3% of deaths attributable to SAB. 
There was a trend towards increased 90-day mortality with MRSA infection (OR 1.28; 95% CI 
1.0 to 15.1) and the presence of co-morbidities (OR 4.1; 95% CI 1.0 to 21.6). The risk of 
complicated infection was higher with non-optimal definitive antibiotic therapy (OR 8.5; 95% 
CI 1.8 to 52.4), female sex (OR 3.8; 95% CI 1.1 to 16.3) and community-acquired infection (OR 
7.4; 95% CI 2.0 to 33.1). Definitive antibiotic therapy was non-optimal in 22.6% of all cases.  
Conclusions SAB-related mortality was high. A large proportion of cases may be preventable, 
and there is a need for improved antibiotic management. 
[Word count: 200] 
Keywords 
Staphylococcus aureus bacteraemia; methicillin-resistant Staphylococcus aureus; antibiotic 
stewardship  
                                            
2 Co-authors: Mohammed Al-talib, Prudence Ive, Tom Boyles, Colleen Bamford Mary-Ann Davies, 
Marc Mendelson, and Sean Wasserman. 
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INTRODUCTION 
Staphylococcus aureus is a major human global pathogen, causing a wide range of infections. 
S. aureus bacteraemia (SAB) is an especially severe manifestation, and a common cause of 
community- and hospital-acquired bacteraemia in high-income countries with a population 
incidence of 10 to 30 per 100 000 person-years (Laupland et al., 2013). A number of clinical 
predictors of mortality have been identified in these settings, but there is limited knowledge 
regarding optimal antibiotic management (Rahal, 1986), and outcomes remain poor 
(Forsblom et al., 2011; Holland, Arnold, & Fowler, 2014; Kaasch et al., 2014). Less is known 
about the incidence and impact of SAB in low- and middle-income countries (LMICs). The 
burden is likely comparable to high income nations (Reddy, Shaw, & Crump, 2010), and may 
be higher due to the influence of HIV infection (Larsen et al., 2012) and differences in health 
care systems and infection control practices (Van Hal et al., 2012).  
Three previous clinical studies of SAB amongst adult patients have been conducted in 
South Africa, two of which were retrospective (Perovic et al., 2006; Smidt et al., 2015; Willcox, 
Rayner, & Whitelaw, 1998). In the most recent study, the number of patients with 
complicated SAB was not reported, nor were the overall outcomes or choice and timing of 
antibiotic therapy (Smidt et al., 2015). Because of the paucity of good quality data, the 
contemporary management and outcomes of SAB in South Africa are not well understood. 
We conducted a prospective observational study to describe a cohort of patients with SAB, 
assess outcomes, and explore the factors associated with complications and death at a South 
African referral hospital. 
PATIENTS AND METHODS  
Study setting and population  
Participants in this study were recruited at Groote Schuur Hospital, a large academic referral 
center in Cape Town, South Africa. The patient population is mainly from urban and peri-
urban areas, including townships, with a low to middle socio-economic status, and a high 
burden of HIV and related infections, largely tuberculosis.  
Inclusion criteria and data collection 
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In 2013, the Division of Infectious Diseases and HIV Medicine at Groote Schuur 
Hospital initiated a policy to review all new cases of SAB in the hospital. Cases are identified 
using an electronic laboratory notification system whereby the results of all blood cultures 
positive for S. aureus are automatically sent via email to a member of the Division of Infectious 
Diseases and underwent clinical assessment within 36 hours of notification. This analysis 
includes the first 100 consecutive SAB infection episodes assessed since the start of the policy. 
Inclusion criteria were inpatients at Groote Schuur Hospital over 13 years of age, with a pure 
growth of S. aureus in one or more blood cultures.  
Enrolled participants were followed up for the duration of their admission. Routinely 
collected clinical information was entered onto hardcopy case report forms. This included 
data on demographics, medical comorbidities, clinical profile, timing of blood cultures, timing 
and choice of antibiotic therapy, duration of hospital stay and inpatient mortality. The 
requirement for informed consent was waived by the ethics review committee as data were 
collected as part of an ongoing approved clinical registry. Vital status at 90-days was 
ascertained from Clinicom, the Provincial digital record and appointment system. 
Microbiological data were obtained from the National Health Laboratory Service (NHLS) data 
warehouse, and included antibiotic susceptibility profiles, the vancomycin minimum 
inhibitory concentration (MIC) for MRSA isolates, and time to notification of blood culture 
results to treating physicians. 
Definitions 
A new infection episode was defined as a positive blood culture for S. aureus ≥ 30 days after 
a previously sterile blood culture. SAB was classified as community-acquired (CA-SAB) if a 
positive blood culture for S. aureus was first obtained at the time of admission or within 48 
hours of admission. Bacteraemia was classified as healthcare-associated (HCA-SAB) if a 
positive blood culture was first obtained more than 48 hours after admission, or if the first 
positive blood culture was within 48 hours of admission but the patient had (i) received 
intravenous therapy in the previous 30 days; (ii) attended a hospital or received dialysis in the 
previous 30 days; or (iii) resided in a nursing home or long-term care facility. 
Complicated SAB was defined by the presence of one or more of the following: (i) 
persistent bacteraemia ≥ 72 hours after therapy with an antibiotic to which the isolate had in 
vitro susceptibility; (ii) metastatic infection or deep-seated abscess, or (iii) endocarditis 
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(Corey, 2009). Death was considered to be infection-related if there were persistent signs and 
symptoms of SAB or if bacteraemia was present in the last culture prior to death.  
Antibiotic prescriptions were designated ‘definitive’ once treating physicians were 
notified of a positive blood culture for S. aureus. Optimal choice and administration of 
definitive antibiotic therapy for methicillin-sensitive S. aureus (MSSA) was defined as the use 
of intravenous cloxacillin 2g 6-hourly in uncomplicated infection, or 3g 6-hourly if complicated 
infection (or guideline-recommended alternatives). For MRSA, optimal therapy included a 
loading dose of vancomycin at 25-35mg/kg, followed by 15-20mg/kg 12-hourly. Duration of 
antibiotic therapy was classified according to local (Wasserman, Boyles, & Mendelson, 2014) 
and international (Liu et al., 2011) guidelines and best practice (Thwaites et al., 2017). Optimal 
duration was ≥ 14 days for uncomplicated SAB or  ≥ 28 days for complicated SAB (Thwaites et 
al., 2017). Overall definitive antibiotic management was designated as non-optimal if either 
administration or duration was outside of these guidelines.  
Empiric therapy was defined as an antibiotic administered at the time of the index 
blood culture, prior to the notification of the presence of SAB. This was classified as 
inadequate in the following situations: the use of an antibiotic to which the isolate is not 
susceptible or use of cloxacillin or vancomycin at less than half of standard doses for SAB (or 
without a loading dose of vancomycin). 
Statistical analysis 
Data captured in Microsoft Excel (2013) were analysed using R (R Core Team, 2016). 
Descriptive statistics were used to summarize the data, stratified by HCA/CA. Multivariable 
logistic regression with a priori variables identified from the literature was used to identify 
factors associated with complicated infection and 90-day mortality. Variables selected for 
inclusion in the final model were age (Forsblom et al., 2011), sex (Smit et al., 2017), MRSA 
(Cosgrove, 2006; Naidoo et al., 2013), healthcare-associated infection (Fowler et al., 2003), 
presence of comorbidities (Fitzgerald et al., 2017; Larsen et al., 2012), and time to definitive 
antibiotic therapy (Lodise, Mckinnon, Swiderski, & Rybak, 2003; Marchaim et al., 2010); these 
were included based on their effect size on the outcomes of interest. Model selection was 
performed using the Akaike Information Criterion (AIC). We used Kaplan-Meier estimates for 
inpatient survival and time to initiation of antibiotics. For all statistical tests, a p-value ≤ 0.05 
was considered significant.  
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Ethics approval 
This study was approved by the Human Research Ethics Committee at the University of Cape 
Town (Ref: 643/2015). 
RESULTS 
Patient and infection characteristics 
One hundred consecutive, distinct SAB infection episodes in 98 patients were identified 
between November 2013 and January 2015. Baseline characteristics, stratified by place of 
acquisition of infection are shown in Table 1. Median time to notification to the treating 
physician of confirmed S. aureus blood culture results was 44 hours (interquartile range (IQR) 
37 to 53) from the time the blood culture was taken. SAB was healthcare-associated in 67 
(68.4%, n = 98) cases of infection, with 57 (85.1%, n = 67) of these linked to intravenous 
catheter-site infection. MRSA accounted for 23.5% of all infections, of which 82.6% were 
health-care associated. Minimum inhibitory concentrations of vancomycin for MRSA strains 
ranged from 0.5 μg/ml to 2 μg/ml, with 4 (19.0%, n = 21) having a MIC > 1 μg/ml. Full antibiotic 
susceptibility profiles are shown in Figure 1. There were no significant univariate predictors 
for infection with MRSA (data not shown).  
 


































Table 8 Patient and infection characteristics.  
 Healthcare-
associated 
(N = 67) 
Community-
acquired 
(N = 31) 
Total 
(N = 100) 
Age, years 
Age > 60 years 
48.3 ± 18.4 
17 (25) 




Male sex 43 (64) 27 (87)* 70 (71) 
Co-morbidities (any) 
   HIV positive 
   Diabetes mellitus 
   Renal failure 
















MRSA 19 (28) 4 (13) 23 (24) 
Source of infection 
   Drip site definite 
   Drip site probable 
   SSTI 
   Central line 
   Dialysis catheter 
   Pneumonia 
   Surgical wound 
   UTI 































Drip site sepsis 19 (29) NA 19 (20) 
Metastatic foci 12 (19) 15 (50)* 27 (28) 
Data are n (%) and mean (SD). Percentages given have a denominator of N as shown in the 
column heading. *No characteristic differed significantly between the study groups (P ≤ 
0.05 at baseline according to Fisher’s exact test for categorical data or the Wilcoxon rank-
sum test for continuous data), with the exception of male sex (P = 0.0195) and the presence 
of metastatic foci (P =0.0015). MRSA = methicillin-resistant Staphylococcus aureus; SSTI = 
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Endocarditis 
Patients underwent echocardiography, according to local guidelines, for the following 
indications: presence of prosthetic heart valves, clinical evidence of endocarditis, or 
community-acquired SAB. Of the 22 patients who underwent echocardiography, 7 (31.8%) 
had evidence of endocarditis; overall prevalence of echocardiograph-confirmed endocarditis 
was 7.1%. Of the three indications, clinical evidence for endocarditis was the only significant 
predictor of echocardiograph-confirmed endocarditis, with a sensitivity and specificity of 
57.1% (95% confidence interval (CI), 18.4 to 90.1) and 93.3% (95% CI, 86.1 to 99.8) 
respectively, amongst the study sub-population who had indications for echocardiography 
(Table 2). 
Table 2: Echocardiograph testing. 
 Echocardiograph Result Total  P-value 
Positive Negative 
Clinical endocarditis Yes 4 1 5 0.020  
No 3 14 17 
Prosthetic material Yes 1 0 0 0.318 
No 6 15 21 
CA vs HCA CA 4  4 8 0.342 
HCA 3 11 14 
 
Antibiotic management 
An empiric antibiotic with adequate activity and dose for SAB was prescribed in 45 (47.9%) 
cases. Empiric antibiotic choices included carbapenems in 24%, third generation 
cephalosporins in 17%, beta-lactam/beta-lactamase inhibitors in 15%, vancomycin in 20%, 
cloxacillin in 14%, aminopenicillins in 2%, quinolones in 4%, and aminoglycosides in 5%. 
Median time to definitive therapy from the initial blood culture was 51.5 hours (IQR 41 to 67; 
range 4 to 156), with no significant difference between HCA and CA (P = 0.47) or between 
MSSA and MRSA infections (P = 0.28, Figure 2). Time to definitive therapy was not associated 
with complicated infection or mortality on multivariate analysis (Table 3). Empiric antibiotic 
therapy was non-optimal in 52.1% of all cases, and in 90.9% of those with MRSA bacteraemia. 
Definitive antibiotic therapy was non-optimal in 22.6% of all cases, and in 35.3% of those with 
MRSA bacteraemia. Median duration of therapy was 14 days for both MSSA and MRSA 
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bacteraemia (IQR 5 to 16). Of the MRSA-infected patients, 21 (64.7%, n = 33) received a 
vancomycin loading dose. Therapeutic drug monitoring of vancomycin was performed on at 
least one occasion in all but one case, at a median of 48 hours (IQR 24 to 72) after the initial 
dose. The vancomycin trough concentration ranged from below the lower limit of detection 
to 48.9 µg/mL, with 8 (47%) cases below the recommended target of 15 µg/mL. Source control 
was potentially indicated for 36 patients, and was performed in 21 (58.8%). 
Outcomes 
Inpatient and 90-day mortality was 41.8% (95% CI, 31.9 to 52.2) and 47.0% (95% CI, 36.9 to 
57.2), respectively, with 30 (83.3%, n = 36) deaths attributable to SAB. The unadjusted survival 
estimates are shown in Figure 3; median time to death was 35 days (IQR 17 to 62). 
There was a strong trend towards increased 90-day mortality with the presence of co-
morbidities (OR 4.1; 95% CI 1.0 to 21.6; P = 0.06) and MRSA infection (OR 3.6; 95% confidence 
interval (CI) 1.0 to 15.1; P = 0.06) on multivariable regression analysis (Table 3).  
SAB was complicated by persistent infection (blood culture positive ≥ 72 hours on 
therapy), deep abscess formation, or endocarditis in 30 (31.6%, n = 95) cases. The odds of 
MRSA 
MSSA 
Figure 2 Kaplan Meyer (KM) plot for time to definitive antibiotic therapy, stratified 
by MRSA and MSSA. 95% CI indicated by shaded region. 
9 
 
Part C. Journal Manuscript 
complicated infection were higher with non-optimal definitive antibiotic therapy (OR 8.5; 95% 
CI 1.8 to 52.4), female sex (OR 3.8; 95% CI 1.1 to 16.3) and community-acquired infection (OR 






Figure 3 Kaplan Meier (KM) survival plot for inpatient mortality. 95% CI indicated by shaded region. 
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Table 3. Univariate and multivariate logistic regression analysis for a) 90-day mortality, and 
b) complicated infection. 
*p  0.05 
  
a) Mortality 
  Univariate analysis Multivariate analysis 
Covariate OR 95% CI P-value OR 95% CI 
P-
value 
Age > 60 years 3.3  1.3 – 8.7 0.01*  2.6 0.8 – 8.9 0.1 
Female sex 0.6 0.3 – 1.6  0.3 0.5 0.2 – 1.7 0.28 
MRSA 2.3 0.9 – 6.1 0.08  3.6 1.0 – 15.1 0.06 
Community-acquired infection 1.6 0.7 – 4.0  0.3 0.9 0.3 – 2.9 0.89 
Non-optimal definitive AB 
therapy  0.7 0.2 – 2.0  0.5 0.66 0.1 – 2.7 0.56 
Co-morbidity present 3.9 1.3 – 14.6  0.03* 4.07 1.0 – 21.6 0.06 
HIV 1.1 0.4 – 3.2  0.9 
  
Renal Failure 2.7 1.1 – 6.8  0.03* 
Cardiovascular disease 1.1 0.5 – 2.6  0.9 
Time to definitive therapy 1.0 0.9 – 1.1  0.5 1 0.9 – 1.1 0.81 
Time to notification of results 1.0 0.9 – 1.1  0.2   
b) Complicated infection 
  Univariate analysis Multivariate analysis 
Covariate OR 95% CI P-value OR 95% CI 
P-
value 
Age > 60 years 0.7 0.3 – 1.9 0.5 0.9 0.2 – 3.0 0.8 
Female sex 1.8 0.2 – 1.9 0.2 3.8 1.1 – 16.3 0.05* 
MRSA 1.3 0.5 – 3.6 0.5 0.9 0.2 – 3.5 0.9 
Community-acquired infection 2.7 1.1 – 6.8 0.03* 7.4 2.0 – 33.1 0.01* 
Non-optimal definitive AB 
therapy  1.5 0.5 – 4.3 0.4  8.5 1.8 – 52.4 0.01* 
Co-morbidity present 0.8 0.3 – 1.9 0.7 2 0.5 - 9.9 0.36 
HIV 0.6 0.2 – 1.9 0.4 
  
Renal Failure 0.9 0.3 – 2.3 0.8 
Cardiovascular disease 1.5 0.6 – 3.8 0.4 
Time to definitive therapy 0.97 0.95 – 1.0 0.03* 1 0.9 - 1.1 0.2 
Time to notification of results 1.0 0.9 – 1.1  0.7   
11 
 
Part C. Journal Manuscript 
DISCUSSION  
Complicated infection and SAB-related mortality were high in this well-characterized clinical 
cohort from South Africa. Most infection episodes were health care-associated and related to 
intravenous peripheral catheter infection, suggesting that many were preventable. Of 
concern, definitive antibiotic therapy was non-optimal in almost a quarter of cases, and this 
was strongly associated with complicated infection. 
At 47%, all-cause mortality was similar to that found in other studies from South Africa 
(Perovic et al., 2006; Smidt et al., 2015) and other LMICs (Nickerson et al., 2009), but was 
substantially worse than in high income countries, where mortality ranges between 20 and 
30% ( Braquet et al., 2017; Kaasch et al., 2014; Laupland et al., 2008). This may be related to 
the high prevalence of comorbidities and MRSA infection in our population, both of which 
have been associated with an increased risk of mortality with SAB (Allard et al., 2008; P 
Braquet et al., 2016; Cosgrove, 2006; Naidoo et al., 2013). Although the short-term outcomes 
of medical patients at Groote Schuur Hospital are generally poor, with only 65% surviving to 
12 months post-discharge (Stuart-Clark et al., 2012), this does not fully explain the poor early 
outcomes observed in our study, where the majority of deaths were possibly SAB-related. 
Over a fifth of our patients had HIV-co-infection, but this was not associated with mortality 
or complicated infection, in contrast to other reports (Jaliff et al., 2014). This suggests that 
specific host- or pathogen-related factors may account for the worse outcomes observed 
compared to other settings.   
Around a third of our patients were assessed as having complicated infection, which 
is lower than that described in a large cohort from the US (43%) using similar definitions 
(Fowler et al., 2003). There are limited data on rates of complicated SAB, likely due to 
inconsistent definitions and the difficulties in ascertaining this outcome, allowing limited 
conclusions from direct comparisons. Half of the community-acquired infections in our cohort 
presented with metastatic foci, supporting previous reports of community-acquired infection 
as a clinical predictor of complicated infection (Fowler et al., 2003), presumably due to later 
presentation and treatment. As observed in other settings (Smit et al., 2017), female patients 
were found to be at increased risk of complicated infection, suggesting that sex may need to 
be considered when risk-stratifying patients. This association is likely multifactorial, and 
subject to the confounders present in observational studies. However, it has been speculated 
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that distinct sex differences in immune responses to infection may play a role (Humphreys, 
Fitzpatick, & Harvey, 2015).The only modifiable factor associated with complicated SAB in our 
cohort was the administration of non-optimal antibiotic therapy, which is of concern. 
Administration of optimal empiric and directed antibiotic therapy has an important 
influence on the outcomes of both MSSA and MRSA (Van Hal et al., 2012); in one study, 
administration of adequate initial therapy for MRSA bacteraemia was shown to confer an 
almost 2-fold survival benefit (OR, 1.84; 95% CI 1.25 to 2.71) (Paul et al., 2010). Definitive 
antibiotic therapy was non-optimal in almost a quarter of our patients, and in a third of those 
with MRSA. The inadequacy of both empiric and definitive antibiotic therapy, especially for 
MRSA infections, possibly contributed to the trend of increased 90-day mortality associated 
with MRSA bacteraemia. An additional concern is that when indicated, early source control 
was performed in fewer than 60% of cases. These findings clearly identify a need for improved 
management of SAB in our setting. Surveys of South African medical students have found a 
low level of antibiotic knowledge, including for the treatment of SAB (Wasserman et al., 
2017), and this should have a greater emphasis in both undergraduate and postgraduate 
medical training as a measure to improve SAB management. The involvement of Infectious 
Diseases (ID) specialists and use of bedside management protocols are an important aspect 
of SAB care: recommended management strategies are carried out significantly more 
frequently among patients assessed by an ID specialist, contributing to the survival benefit 
associated with this intervention (Liu, 2013; Paulsen et al., 2015; Vogel et al., 2016). Although 
all patients in our study were followed up by members of the ID Division, we did not evaluate 
adherence to management advice. Most South African hospitals do not have access to ID 
specialists, but should consider implementing evidence-based bundle interventions, including 
early source control, and early use of intravenous cloxacillin. These are simple and cheap to 
implement, and result in mortality reduction for SAB (López-Cortés et al., 2013). 
In contrast to high-income countries, where the highest case burden of SAB is seen in 
the elderly (K. Laupland et al., 2013), only 28% of our cohort was over the age of 60 years. 
This may reflect the higher incidence of comorbidities, such as HIV, in younger members of 
our population. Similarly to other settings, (Allard et al., 2008; Asgeirsson, Gudlaugsson, 
Kristinsson, Heiddal, & Kristjansson, 2011; Huggan et al., 2010; Klevens et al., 2007) a high 
proportion of SAB cases were healthcare-associated. This is related to increased exposure to 
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intravascular access devices, including short-term peripheral venous catheters, which are an 
important cause of bloodstream infection (Mermel, 2017). Our finding that the majority of 
SAB episodes were related to peripheral venous catheter use emphasizes the need for 
improved infection prevention practices in local healthcare settings, such as the 
implementation of evidenced-based bundles of care to reduce intravascular line infection 
(Fitzgerald et al., 2017; Larsen et al., 2012; Wilson, Moore, Lucas, Francis, & Gebo, 2008).  
The prevalence of endocarditis in our study was 7%, similar to the proportion of SAB 
with endocarditis in the United States (Klevens et al., 2007). While some form of 
echocardiography is generally recommended for all patients with SAB (Holland et al., 2014), 
this is not always feasible in low resource settings, particularly for transesophageal 
echocardiography which has a higher yield than transthoracic imaging. Clinical guidelines may 
be a useful strategy to identify low risk patients not requiring echocardiography. Although our 
study was not designed to evaluate this, and the denominator was small (n = 22), 
echocardiography testing according to local guidelines, namely those patients with implanted 
prosthetic heart valves, clinical evidence of endocarditis, or community-acquired infection, 
was able to identify endocarditis with an accuracy of 72.7%. Only one case was diagnosed on 
echocardiography in the absence of these indications, suggesting that these clinical indicators 
are useful in ruling out endocarditis. However echocardiography was not performed on the 
entire study population, and the results are therefore not necessarily generalisable to all 
patients with SAB. Future studies should be undertaken to define better the indications for 
echocardiography for SAB in LMICs. 
The proportion of our patients with MRSA infection, at 24%, was lower than that 
reported from South African tertiary hospitals in Gauteng from a similar period (36%) (Smidt 
et al., 2015), but is on par with other results from local state sector hospitals at earlier periods 
(Naidoo et al., 2013; Perovic et al., 2006), suggesting that the incidence of MRSA bacteraemia 
is stable. However, local rates of HCA-MRSA are substantially higher than those reported in 
high-income countries, which are generally under 10% (Forsblom et al., 2011; Tom, Galbraith, 
Valiquette, & Jacobsson, 2014). This reflects challenges in infection prevention and control 
(IPC) services in South African public hospitals, many of which do not have antibiotic 
stewardship programs or dedicated IPC nurses. As expected, almost all MRSA cases were 
healthcare-associated, reflecting the absence of the ST8:USA300 strain of community-
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associated MRSA in South Africa (Goering et al., 2008). However, there were a small number 
of cases of community-acquired MRSA bacteraemia in our cohort, emphasizing the need for 
clinician awareness and ongoing microbiological surveillance with accurate ascertainment of 
site of SAB acquisition (CA versus HCA).  
Despite definitive treatment being delayed by 24 hours or more from initial blood 
culture in most patients, this was not associated with an increased risk of mortality, as has 
been observed in other studies (Lodise et al., 2003; Marchaim et al., 2010). It is possible that 
the negative impact of delayed therapy might have been more clearly seen if a higher 
proportion of cases had received optimal definitive treatment, or if the levels of antibiotic 
resistance were higher, with decreased adequacy of empiric antibiotic therapy. This delay in 
definitive treatment reflects a delay in the identification and susceptibility profiling of S. 
aureus from positive blood cultures. The use of novel tools to identify S. aureus directly from 
blood cultures, such as fluorescence in situ hybridization (FISH), polymerase chain reaction 
(PCR), immunochromatographic assays for PBP2a and other methods have been shown to 
quickly and reliably identify S. aureus (Buchan et al., 2015; Delport et al., 2016; Felsenstein et 
al., 2016; Oliveira, Procop, Wilson, Coull, & Stender, 2002; Thomas, Gidding, Ginn, Olma, & 
Iredell, 2007). The use of such tools in our setting could be valuable in encouraging prompt 
antimicrobial treatment of SAB and an improvement in patient outcomes, although cost may 
be an important limiting factor. 
While the management of SAB in our setting is inevitably affected by organizational 
level facors, resulting in delays of organism identification and reduced rates of 
echocardiography, the results of this study can be used to inform management strategies in 
various ways. On a clinician level, improved knowledge regarding recognition and treatment 
of SAB, especially infections with MRSA, is key. While infectious disease consultation and 
guidance is important, so too is ensuring that the advice is followed, and that the patient 
receives the medication. More regular input is required with drugs such as vancomycin, as it 
requires a loading dose and additional monitoring. Clinicians should be actively encouraged 
to seek guidance when prescribing antibiotics. The high proportion of infections related to 
intravenous cannulas highlights the importance of intravenous cannula care and monitoring, 
both as a prevention strategy and as a part of source control.  
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The major strength of this study was our ability to accurately evaluate the setting of 
infection acquisition, and prospectively capture well-defined clinical outcomes and 
management practices. There were, however, a number of important limitations. The 
relatively small sample size resulted in reduced statistical power and generalizability. Because 
of this, important risk factors in the greater South African population may not have been 
detected in this cohort. For example, because source control was only indicated in 36 
patients, this variable was not included in our prediction models.  It is possible that the use of 
the electronic notification system may have resulted in cases of SAB during the study period 
being missed, which could have biased our findings if the loss was non-random. SAB incidence 
has been shown to vary between hospitals within South Africa (Smidt et al., 2015), which may 
further reduce the external validity of the results of this single-site study. Future studies 
should attempt standardized collection and analysis of pooled data from various hospitals 
across South Africa, with a particular focus on SAB management 
CONCLUSIONS 
SAB is strongly related to intravenous peripheral catheter infection in our setting, and 
mortality is notably higher relative to higher-income countries. Non-optimal antibiotic 
management, especially for MRSA, is a significant problem and may contribute to these poor 
outcomes. Cost-effective prevention and treatment strategies should be implemented as a 
priority to reduce the burden of SAB in South African public hospitals.  
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Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see more 




As an author you (or your employer or institution) have certain rights to reuse your work. More information. 
 
Elsevier supports responsible sharing 
 
Find out how you can share your research published in Elsevier journals. 
 
Role of the funding source 
 
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the 
article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the 
funding source(s) had no such involvement then this should be stated. 
 
Funding body agreements and policies 
 
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's 
open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details 
of existing agreements are available online. 
After acceptance, open access papers will be published under a noncommercial license. For authors requiring a 




This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. 
To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which 
needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party 
(re)use is defined by the following Creative Commons user licenses: 
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For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an 
anthology), as long as they credit the author(s) and provided they do not alter or modify the article. 
 
The open access publication fee for this journal is USD 1750 for original research articles, reviews and perspectives 
and USD 600 for case reports, short communications and medical imagery, excluding taxes. Learn more about Elsevier's 
pricing policy: http://www.elsevier.com/openaccesspricing. 
 
Language (usage and editing services) 
 
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who 
feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to 
conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's 
WebShop. 
 
Informed consent and patient details 
 
Patients have a right to privacy. Therefore identifying information, including patients images, names, initials, or 
hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless 
the information is essential for scientific purposes and you have obtained written informed consent for publication in 
print and electronic form from the patient (or parent, guardian or next of kin where applicable). If such consent is made 
subject to any conditions, Elsevier must be made aware of all such conditions. Written consents must be provided to 
Elsevier on request. Even where consent has been given, identifying details should be omitted if they are not essential. 
If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide 
assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been 
obtained, personal details of patients included in any part of the paper and in any supplementary materials (including 




Our online submission system guides you stepwise through the process of entering your article details and uploading 
your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., 
Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of 
the Editor's decision and requests for revision, is sent by e-mail. 
 
Submit your article 
 




Authors must suggest three non-conflicted peer reviewers with expertise as much for content as for methodology of 







Part D. Appendix 
Peer review 
 
This journal operates a single blind review process. All contributions will be initially assessed by the editor for 
suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert 
reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding 
acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review. 
 
Use of word processing software 
 
It is important that the file be saved in the native format of the word processor used. The text should be in single-
column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced 
on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. 
However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use 
only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align 
columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also 
the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required 
whether or not you embed your figures in the text. See also the section on Electronic artwork.  
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your 
word processor. 
 
Essential title page information 
 
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and 
formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check 
that all names are accurately spelled. You can add your name between parentheses in your own script behind the 
English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. 
Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the 
appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the 
e-mail address of each author. 
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also 
post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure 
that the e-mail address is given and that contact details are kept up to date by the corresponding author. 
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at 
the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address 
at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals 




Manuscripts must be accompanied by a covering letter stating that the current "Instructions to Authors" have been read 
by all authors, thereby indicating compliance with those instructions and acceptance of the conditions posed. The letter 
should state that the authors have seen and agreed to the submitted version of the paper, that all who have been 
acknowledged as contributors or as providers of personal communications have agreed to their inclusion, that the 
material is original and that it has been neither published elsewhere nor submitted for publication simultaneously. In 
addition the letter should state that if accepted, the paper will not be published elsewhere in the same form, in English 
or in any other language, without written consent of the copyright holder.Please also note that Authors should provide 
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a list of 3 potential reviewers (e-mail and affiliation) who are knowledgeable in the subject matter, have no conflict of 
interest, and are likely to agree to review the manuscript. Please ensure that 2 of the potential reviewers are from a 




A structured abstract of 150 to 200 words must be provided as part of each manuscript, except correspondence. The 
abstract should consist of four paragraphs, with the following headings: objectives, design or methods, results, 





Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The 
graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the 
attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission 
system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The 
image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, 
EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. 
Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in 




Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core 
findings of the article and should be submitted in a separate editable file in the online submission system. Please use 
'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet 




Immediately after the abstract, provide a maximum of six keywords, avoiding general and plural terms and multiple 
concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the 




Abbreviations in the text are discouraged. If a term appears repeatedly, however, an abbreviation may be introduced 
parenthetically at the initial mention of the term and used thereafter in place of the term. Abbreviations of 
conventional or SI units of measurement may be used without introduction. 
 
References to drugs 
 
The generic name of a drug should be used as a general rule; however, the full name or the commercial name of the 
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Microbes should be referred to by their scientific names according to the binomial system used in the latest edition of 
Bergey's Manual of Systematic Bacteriology (The Williams and Wilkins Co.). When first mentioned, the name should 
be in full and written in italics. Thereafter, the genus should be abbreviated to its initial letter, e.g. 'S. aureus' not 'Staph. 
Aureus'. If abbreviation is likely to cause confusion or render the intended meaning(s) unclear the names of organisms 
should be given in full. Only those names included in the Approved Lists of Bacterial Names (Int J Syst Bacteriol 1980; 
30: 225-420) and/or which have been validly published in the Int J Syst Bacteriol since January 1980 are acceptable. If 
there is a good reason to use a name that does not have standing in nomenclature, it should be enclosed in quotation 
marks and an appropriate statement concerning its use made in the text (e.g. Int J Syst Bacteriol 1980; 30: 547-556). 
 
Symbols for units of measurement must accord with the Système International (SI) 
 




Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, 
include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help 
during the research (e.g., providing language help, writing assistance or proof reading the article, etc.). 
 
Formatting of funding sources 
 
List funding sources in this standard way to facilitate compliance to funder's requirements: 
 
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda 
Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa]. 
 
It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a 
block grant or other resources available to a university, college, or other research institution, submit the name of the 
institute or organization that provided the funding. 
 
If no funding has been provided for the research, please include the following sentence: 
 









• Make sure you use uniform lettering and sizing of your original artwork.  
• Embed the used fonts if the application provides that option.  
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look 
similar.  
• Number the illustrations according to their sequence in the text.  
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• Use a logical naming convention for your artwork files.  
• Provide captions to illustrations separately.  
• Size the illustrations close to the desired dimensions of the published version.  
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are given here. 
Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as 
is' in the native document format.  
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save 
as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, 
and line/halftone combinations given below):  
EPS (or PDF): Vector drawings, embed all used fonts.  
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.  
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.  
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi. 
Please do not:  
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of 
pixels and limited set of colors;  
• Supply files that are too low in resolution;  




Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and 
with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will 
ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) 
regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in 
print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate 




Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should 
comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations 




Each table must be presented at the end of the manuscript on a separate page and numbered in order of appearance in 
the text. The title of the table must appear after the number. Each table must include appropriate headings. Footnotes, 
when necessary, must be identified by letters. Units of measurement must be clearly indicated. A table can include 




Citation in text 
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Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references 
cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in 
the reference list, but may be mentioned in the text. If these references are included in the reference list they should 
follow the standard reference style of the journal and should include a substitution of the publication date with either 
'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been 




As a minimum, the full URL should be given and the date when the reference was last accessed. Any further 
information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web 
references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included 




This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and 
including a data reference in your Reference List. Data references should include the following elements: author 
name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] 
immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not 
appear in your published article. 
 
Reference management software 
 
Most Elsevier journals have their reference template available in many of the most popular reference management 
software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, 
as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate 
journal template when preparing their article, after which citations and bibliographies will be automatically formatted 
in the journal's style. If no template is yet available for this journal, please follow the format of the sample references 
and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field 
codes before submitting the electronic manuscript. More information on how to remove field codes. 
 
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link: 
http://open.mendeley.com/use-citation-style/international-journal-of-infectious-diseases 
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft 




Text: All citations in the text should refer to:  
1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;  
2. Two authors: both authors' names and the year of publication;  
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.  
Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then 
chronologically.  
Examples: 'as demonstrated in wheat (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have 
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recently shown ....'  
List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than 
one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the 
year of publication.  
Examples:  
Reference to a journal publication:  
Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2010;163:51–9.  
Reference to a book:  
Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.  
Reference to a chapter in an edited book:  
Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. 
Introduction to the electronic age. New York: E-Publishing Inc; 2009. p. 281–304. 
Reference to a website: 
Cancer Research UK, Cancer statistics reports for the UK. 
http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13 March 2003). 
Reference to a dataset: 
[dataset] Oguro M, Imahiro S, Saito S, Nakashizuka T. Mortality data for Japanese oak wilt disease and surrounding 
forest compositions, Mendeley Data, v1; 2015. https://doi.org/10.17632/xwj98nb39r.1. 
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed 
followed by "et al." For further details you are referred to "Uniform Requirements for Manuscripts submitted to 




Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who 
have video or animation files that they wish to submit with their article are strongly encouraged to include links to 
these within the body of the article. This can be done in the same way as a figure or table by referring to the video or 
animation content and noting in the body text where it should be placed. All submitted files should be properly labeled 
so that they directly relate to the video file's content. . In order to ensure that your video or animation material is 
directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 
150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of 
your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any 
frame from the video or animation or make a separate image. These will be used instead of standard icons and will 
personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: 
since video and animation cannot be embedded in the print version of the journal, please provide text for both the 




Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. 
Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such 
online). Please submit your material together with the article and supply a concise, descriptive caption for each 
supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make 
sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track 
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This journal encourages and enables you to share data that supports your research publication where appropriate, and 
enables you to interlink the data with your published articles. Research data refers to the results of observations or 
experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages 
you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the 
project. 
 
Below are a number of ways in which you can associate data with your article or make a statement about the 
availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are 
encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more 
information about data citation. For more information on depositing, sharing and using research data and other relevant 




If you have made your research data available in a data repository, you can link your article directly to the dataset. 
Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving 
readers access to underlying data that gives them a better understanding of the research described. 
 
There are different ways to link your datasets to your article. When available, you can directly link your dataset to your 
article by providing the relevant information in the submission system. For more information, visit the database linking 
page. 
 
For supported data repositories a repository banner will automatically appear next to your published article on 
ScienceDirect. 
 
In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the 




This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, 
video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access 
repository. Before submitting your article, you can deposit the relevant datasets to Mendeley Data. Please include the 
DOI of the deposited dataset(s) in your main manuscript file. The datasets will be listed and directly accessible to 
readers next to your published article online.  
 




To foster transparency, we encourage you to state the availability of your data in your submission. This may be a 
requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will 
have the opportunity to indicate why during the submission process, for example by stating that the research data is 
confidential. The statement will appear with your published article on ScienceDirect. For more information, visit 








Online proof correction 
 
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and 
correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment 
on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone 
process by allowing you to directly type your corrections, eliminating the potential introduction of errors. 
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing 
will be given in the e-mail we send to authors, including alternative methods to the online version and PDF. 
We will do everything possible to get your article published quickly and accurately. Please use this proof only for 
checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the 
article as accepted for publication will only be considered at this stage with permission from the Editor. It is important 
to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as 




The corresponding author will be notified and receive a link to the published version of the open access article 
on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For 
an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for 
publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Authors 
requiring printed copies of multiple articles may use Elsevier Webshop's 'Create Your Own Book' service to collate 
multiple articles within a single cover. 
 
 
 
